• KSAN
  • Contact us
  • E-Submission

Korean J Adult Nurs : Korean Journal of Adult Nursing

OPEN ACCESS
mobile search button mobile menu button
Search
Advanced Search
ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS

Articles

Page Path

Original Article

Factors Influencing Health related Quality of Life among Patients with Chronic Hepatitis B

Ja-Ok Kim1, Man Woo Kim2, Ja-Sook Kim3, Su-Jeong Han4, Sehyun Kim5
Korean Journal of Adult Nursing 2014;26(3):287-299.
Published online: June 30, 2014

1Department of Nursing, Wonkwang Health Science University, Iksan

2Department of Internal Medicine, Chosun University Hospital ․ College of Medicine, Chosun University, Gwangju

3Department of Nursing, Dongkang College, Gwangju

4Department of Nursing, Konyang University, Daejeon

5Graduate School, Department of Medical Consilience, Dankook University, Yongin, KoreaJFIFddDuckydqhttp://ns.adobe.com/xap/1.0/ Adobed     ! 1AQa"q 2#w8B36v7XRr$9bCt%u&Ws'(xy4T5fH  !1AQaq"2B Rbr#u67Ѳ3sTt5v8Sc$4ĂCÔ%UӅFV ?_Aנj- H>>,m*>fzp"TrKkr^r.|_&]|*vPuܶvoQ1mwVJUhu-I"=LniAƕ8"۲ k*ҿ[yu:.vUQ+)%F DHyVBk>Hy8jݹ q~9D4KRmzQ)^ʔ.J%k_tVi5NTjg!'ky|5asOȻ)R۸ߩFMԿ3L4j6dڜ#NIwUF]JqB/(FafJRzq3\G՛ ?~\ 6)6W4m[O^L0E&rRMض*C .]Unl-1 1r#Rj/&QɈ׉˩s6Rj=5Tg.y.·Pӡ:JJS:C8-2u]d&vUz;7p9 5VnL֢"y)">iי(IDDd| Yj0; LRfS:ktYK%*N2^m|&dğth":ey)uPQZW)gcC3Pv&MMWd&Ŵ۲mvTRoժM03*F3Yd6\8,\hݻ kߔi<k NTwSԪmljj[>->ptU%'LR>&EBH$MQAUx[$Z6vi&_a.KIQ{hyƒ j"JOC9eFҝfj;˚Ω<[3_m% lQ@4g=5$(J]Yc-OMq<Ǎ wSzڗ)k$7VIP붾ͯnV+卵*t]iЎD31~SA1éC2u)ʼnQn-Uoi3:grI8ؓWm*G zܕ)ZקJ}Y YlGeJ6cB2I NS3Q>k=KTBT]W6+SOXQgGR? telˊ%-Re\hѯ2TF"C/OJΩ6r[N.0{SpljjX1“jOsӥ;ҭhe}xu`Ք&.)yO̒ Fߑ.$Qw;9Iw2o+RVJMSOj[SoҌZ%;`d$blQ{Ro{Imڌ>3egf\O֝Uzx"䢸g+mv%Gʆ:|V[N'&ס-ޝ'kfE|K,G&˳98Juin/\\Qݿ̋v~Ǩ!rtWU d|E߫R4d}.qPw*Ӭv5YEcn~f5c%MTMkb-F>5JT,})QHg%{("ӔȸWMsYyWNRrkkJr0XドnͫT}r-jj,Ŕʍ\Q2Ri>v$5!]"JB2WɅ)]VԜUc8i|.jeRO6^V.¸ Q&#|ܶ-*uOG%JAtRZRr]FFG\۩w+?'zչSѧt jz>KW&ot{7P&2D;&\\>Q2JzܗAKSfeNn[jRrԕf6,q,F1tRfԗ>vֶևj-&R'Zi2=xv~Elbsvm8=ӛ"ū񕜈BȩlWau[]ٷBߨF~J!|Ipr3R̴#Yp)={7:G{+:\W}n|Q#%)7^-h"Ƒq:M*%J&$T軨I333׎g_- ucBwwjp[6i25$̏bU’ٱRv?G\~#Iͪb7<<}Ezt" q_Inw,7-d,G÷%T* Wg1"䥱kq/A.,_KhqŒxwvo u2ۥۧ.bQ}XκA$֣ +K״ZUNmڸII{.v{5z5ѮRme[moyƾd~cRݾK'j.\i&/S6f|b=5: p!6i_ 4j6=.si˧eƾtS^c.Y^RJVS-Vi3,esi08?H$GvZgg?gi䤟2adw릿:"۪lkSN>q-4kI܋ێe̊qۅgDoѨ9; #T.Q;7#~_Ufstb_'w~Xw1Xk,vcOt._}v}8"(4Z\ۘgk?J?bm_c!g{HZV]Fkk%~gEt)b秴vΰB|꽸}mp~E6ݹv;7P٤v+ri*3Ԣ|'O14_~7nP{7ZU\Vű[ +7󖱅o#:ǥŬ\|3r%TJX]V7ez¨Y]lc|O3V! R zbJ'PnGqVJ"19WVeOF埜EaEJωqCN5Z g-9[S<$sUK5b|7sn\7x qmv##FF\ w[=-43$^ooVSiXօv7iB۴yg>]Vf"r$J3""32!Zh[K%7GvNLs+4nB/B{vlsobJaҺJR:0g%&zR\ S3T[&ִor*ⷳc3ʊO[iozW٨%$gn:ܶWwFBԹjHP&z u&F2\f;ipW73 [; '_̽b;vib!oec dC-tS__$Xs]l9&z$2/N>%'[}b{h/{`{Ji׉׏ YJB/X%}.|+{(S:qz]4_Kѵo`^tY_4S#* ^zvݾMr+TrkQ g.8Ͽ^i>ӈǙvix>$o( ^qt*&t1oJVu-ql5U6jCЉmĻ*"?JT=K'O/|=Vo}l0b}}f?X[?/\JSBe,kP8ETJ==?.p5ފgbU9}ǶdNKk—_$8̸͓ۍ8Di\BԿ-1v{FF]|.^ۅ{vl12׏z7-R7wE?\nh\jN/Kձr_oBw"N QMBZqe-m:ӨSn6j4%!hQ;sv'm4kcM=!8\m[M4{SMliۇ%eֽR&N:{2A8)THLK3Zj[jPBx#BگMf:G1\`edcʮ?|w(-̮vXt,bW2;.ιNHRR#YwTM"<;mk\.foIDjmlJ;vxy7o7i\,KQŊ9d^Mmgc L*.T6tLeIuOH3SJQ3=F/ʿ<9\JM6mN6=<{xkP!F1QR[I$6ُimXu2An2yԒMU q f[IB-'䤯jYm52&JG\zд\~vdg QtHGXw&1Lw+nDEdC1w|YJmvP)HZ>i0BPβә?R:QO["]I_Jʏۍ>QKyu^bycBq4lXF~l [\*N>-J6,Gq(Zr5h]CwYӤU~ʶߑ u*SIv%ZfJ7)! FS*s_\|IŸZ)J ]ܜi4"z[+Z,MOZ))}|Ʀ(RUNIII.S'ˍO~˨rn}M)xxӕ0 eyҵ7YMAB]ӣU:/ѭ*6bcwP͵ "+qēVjŹO|GtY4V j[mLV M -m>",B$ GD1~j6O4|LxnNmqATNR3ε|DŽa[fmn-ڭ+FiK7Pcm;r5 l8r{#-]'nrFh2ruycb;pW=njRqRJ(d mnpckNnʹ+6]tz~E=ʕ l ZZ5jSi3#47.Lcfe`9؏v囜.F\-UZ:*0_<Νu9Lӵm&)_3\^ҹ3"1n1v_|uRʞͫr'iȧN_kH׺8xXrj=\МH)V\ˬ.Xʸ oVRC}ySU9/OBY먌5 ٿwޞ)rw8Ӫi5*5ZΗcGƱ !ZۄlmpjJ -l <R̵/JAպZuq\IdUS 48wXJJtcg4cI~aqߓwŷrm-v)G7yS^7H^-\mŌAq|"m9IBnF㏉9[N+mmy/!KKۉ%n +BdddfFF6FQRN-U5;Sv'm4kcM=Mn)\qιqUd9F%",6MGdT%-+~ f%+y֛^3SrF>6lc(֪vۊN;g._0Sѧ]ETWرkQKzGe9ʨsKA"yC y2\[5 rԭ7Gk5Mzw_4sM3hxЊ'oÍ5jsub )ͪ~tR2H]R͍>̋m6=%(˿(Wrr-܅y5(ܔJ޺YunW̹븹NsqK ]/QR#"ZMDfD|43Qw|._ԡSqTZBg??O Ϥ)/E_U|i}2 9Z?¹0:x'3,whǣ?C y-A~=daJј&M?D1_PS+Oi&;a @;Dž7[ zZC"bv:jjMQk$M RԸ3uA\=wI.AwC"^.{?-\NSiˏ"b}T/}q/ o.1M}R%:-ZniʒL$SgrBW*,Mw'N\ɇ{s\j]VryG'8f`}'N<*/`U숻z CwHq18J+vԕKss4R53/&XTt1bZƟo\=%nO)h$rBi-nKĪ^ ջڜlwkYm[̑+/QrZo%TQ;TLs($2C:s.%+eoNttq۰kK7O0m_t_pZ1SsSM7"mevFZ[w -FJ*T*jФQRg BSu|]g:ɵzjqwmltL.e3sRMچkSmjkmWœިm++¦'tILk*բQ D,PB\lI[9{%Gb R6öۍmX-MaʉA931cs..G4CujQտ[9 }G-xwl)IQz j Ó"rqe&=]꾧֎c)<kӳ+0JrRR3'TnXi^xMF Bު*tIL.[h"2"nKzZe'ZV/RrNYz]8죝n]Ķܩ>^Ժ]u-7^\mZjܣ9+Rmn ߑv?oꋘ?&ƪy^N4o=3-ؔ̿*`}V݁ ƒPu8%$ ݗ]wt;\y\>='OjPIp/nJU8{϶FNMsf"ίNqƹ(+ ݮF2Km |jܴZs%zf*eȫ?]4)I۵nR&FX + [jDh(#哑9q9Eծj8noǕZf\J-l&Z˫}`ӎhyrΉn\űn]9pʌӣ"׮Wt?N4_I_~54#/my1Xr*척aS#DT >q ssΛW;3oUaJSRMDgQnt:Ql,/ ܷfRqiM Ȼ>Cob;A>ڦWقM9X~/!'MW.}Vrߔꔵ!5|iB(0-zF=}okڢE$^wW~nokY߮\6՜̌{i-AF*9)\t9IV6۸5ZUF6R$ŨQIq砳YUZ]eyv >hI櫥N )&l JulwE1GDOuFN2| }馥uC1rޫV+^gdb&W[4<^e4YW,d|htͮsUM)۸8:{3d{AѢ)~ \#J=NdƮꮓ90 |1K$v*?мS ]i$J,C,SG?/_՜pMSƯM|mG1V1$~K>CSvkuj=&) -,yLjuFHK{c駗.SOua;BrSqj-ۍZ#'Jys7[g2z/.u4+XV2VQ.ޕ)$"(%)#Z7suZ%j }BǬݕe)Jvz8zJf:hIN|svO1O#IEcۍjݽ:SdὮvu^@:o^5cs>i/VqmVm]ؔܢn6'vޑ̗J4Wn@OlKbX ;n:hgJ9ŻyǑz8f܌q&Y fN0N;[69 rbׅC2/#kE l&2~èMR.*%g=Ft.%؝e8<.e=Uv{~㻏"EˑnvDѭ͜Lu3u0:U֝$[M5<:oi+V4V9 6nXvx&_ q Qqw3W:uϔ2yb/(ɳ|5zQiJ#r|Hw#.W?4aDŲ\ugWG;Cw鐢K|xg)##=O.dF˟jMUvWĻsr.z]kPc9"]R)mkfOd*uYf١RsB Aîh=k]ʳUrrZsq`d#r$/Ը3o^&lRWȍyuW̦Y4QDUMJ65ƒ[+ygk XK_±k#y:8(TJOSQhJt2.DR}"5[) r)6V6u5k:eXZmv𭤔!푊Q[qQ}ҹLE- 8qIZG|UM4j}Mܕ[Vwm{} Naqµ"ԈM zOpKѰ?IAD3Ir0'/q1itoB5{%wkOBn-ۜduqIzYK60{+DʕܞqIt";r1mG/\/ym[6JƫR \L=S=OT@Ix[TMm{>ݾտ֒ݸӉLYIx>+"JVNzx||5rI?C{oz8۹e\R-^\A2F R+N9 vlT]"ۭ d)t֞i #E2jB@׵=#/N+!ĕhx}I!cM`ąZ*ŻɄҒ߮Y.Z}='/oۙ3IpW̮hT7cTSuz9>B}΄&h!>lӵn~j˅IvU.'v'CSZw8QK3G> ,J59ٷ+HSg䧎hJdzvwv-cvxS5[̊n~ؿ%ַX?O0\6ne 6kn9.ϯ} *h 8_QhLݣ7q +=XBҲ5?[[)+F`=4 }B,sNg==u*Nj9k_GJ)+R~GSPBȒZ:(K]heL=vKPӢwq(NrG^ثϣ?#tC?.ͼ[ۅo؞y#%ǛjVyLSw%T*s92JTM%"YkQО.q)gCͲn8cgi6j1MѾ[{9h^vƘǚםidfi.^RHmg&rׇz:}݃}xT$ضk'5s-狶,\vpbPD،=Okf.c#cdz2FK5T!&)|ntD<+OŹU i-G[EE*FDfeaf2QƤM\UG_{ǹm%\yrGy:.\4wjPGUJޕUV7Do\7Vy_13w;[?c]H\$IJ,*L]3b%L{y.JRKG2sq,B6T}(#nW|km+q5] r㪍bJ@y{byz,b踊3ϻJ,'^xd،)JVw#.Vټc''ÝպWtbRؒJz۠8!o9IۄS95E9ؔ-e9JR{dmnｯ<[~n${~Њ$W?&ՐY_? #a.ߑv?oꋘ?&ơ|y^N4o=3t=~7!/M3>n8W홎2M`Qx+ z qy8%]7_~540ۦ彷]Wq CѡwkďyF5Dum_}~P(5.(X,K9vᯐ?leB9;Jhm#3{CxGE-S{;@Fz˙]=O'!ɿ]' r`:7'2bЖ>Iy,/eTy/V<.H?UYY{\^#ѣr9^7?xoRȆ7EoS_&??zϾM?(~Q-K&>"~aߨ t7Emsϛ+?;fCr)fY+>z$tIkjn_>vnrֳki-˹l= t;'EyC¥|/BLwBJdgjۛ$s S1|ɍV%JI6KvəhzIlBYɒ|0"Sy0F>eo5W)O+X˻u';v)2vVq۳kۮws?UʑBǴYO漪e2MIjPAک\b1)DDؚKm6ZWΨgȕ۶yjڳ 2ضN[C[|r@9Jfo<_eI7q.|cÊV߷:i.:$ȋ)1%%)ADZCEBxJ0MJۥy(bNsKM9k43IwNt.\%N簤I'.j|ƃ2$grBEٌ\}9:v*!n7M(ɽ]7c@XxƱԨ37īf62cTTfFK]9wntQHͮvٱI/f|j=7}\_V5U^+:uljSȃY(XI.ȱmo1甅jڎIZ2>#\*:gY|4k\8ZwSqtyA!+];бޞKծË¥e)#5ap.QK^8VdU{*ѽL\=qmjnB5>{ Ӟ`v±5 ^k&O~Oshɷ,;6nOW>u6{RqS`)S%jp\ipdEBLfTWy$GIYw~䲭J.1vSY5z.V>^+Ǎvc.I[R{QsNR3ӎfhd>y?UJ*}~[e\i5U^͛E]G_FS(Iɿ]i8:4zj~շsW,ˆsy:%O}iur]iF5~3M:Ӟ#N06)4ߧgdawIotiz:1r5YDZLHBSi;NQc44la=Y kQIT*ըl:tq2(է9VO4뒳܂~2rq'nrVZŦ[t7\oլfb/mlpc.I8콚q^1iE~䰳mi[dۧw֤ICfdFeCsg:i| 6擣׋* 96lust^{%99UNRvaMܽo ammi$em4D6DD\nA%$$#}۷/ݕr99JMն[oT޲E"KTaP+HGkŴj5TM5xƱOS-k`ۛkٝWz;{kS}F;~q|~^_|euwnE'pSupUP)V]vE+t =ZRaVdG6= *.ϼnj9:UɷbېmF_tޫgHjVS'śǕًdkkѻ_]Kv?nT>)^e=Ar1'3ԔILyD?:-^in):{7.؂\.:V }#뺾.3r̸*xbFM aȵz 6SQ:ײj[ 8nn iFMw rR"5M5I旘35f^j='j:nNW.ʭocZvZKV^ɚJ.cM1ZI7E'6rg탸5oZ=[m Z`\hbMUR١Ȗĉ):Jin!_7Dй+f̷eKҷvͨBPR(V`y6tw*MRΝcB.ڭTnc;P$8nFvm4(D(R#R-L -2:FP lxZKQc6I("Km%$E, 78uXIFA$RQI$JbInG]c[ֹ:ZM+n^')JmJMJRu{e)7jQDw~%yQl}BZujSSf۩QZ+Dzhd5o%BIc'GZ?}΍:>Ɵivז-%݌J5MqGWTVʦh݇ܟ~Օ_6 n'{3~mϬj'J11OȻn߃r Qr\3y٘+WӍ'WxEs^O3 o~[|7>]]H9݇ZomT@]?5B:Z߂'`V_+/MSKX߆ޠk3?o7y:4R/7þ] iG߬aBRU&?r&/} cQߥGj2?C5Yśe7hU=?+ x龳f-܈czW^7p%-(\D4h{UK&ӡn^m]Fݢ:`δvj俜F+) y[{{ 7 tu>gvrěOj'5 iRg[ͶFjGe n~qT$ci ۚ0oԹc*jL[sVWqj\ݻ&6"WoK:cnWmrv)o>66(F>=W^bf#c zzʞtپy%mՉPël e}J.\Zk4ttt>oEM=q)hJjI=ͥ(%]脼_88ф;͛gWG;Cw~˘$4=uWdĜTثNDkiQL9U*O"4XP`02,Ge-k5$h>ܼ]3vr6!9RQPIVSnM(ۓ{>;/Qͱv{3&-[rc)ܚI$n{Sv3[j00)-D3z}MRzVQпj,T[uVs0\}Sid;r(ݝJ>æʺL&c[jPK0~d(FKÝW\m]GTcF|Iׁ)I3~#oX%vҦEݑؼ5Żv2qAZTE^..M{ʐfȏ2##.R}*KʛZz^ӞN*lPťLf\G6[WVQquV]XAi)5J!,$iJ6o$tPZc;Kjx_n3`qIelV~vLy{fn匋Ѿn%;zV.n'-ұdd2߽1bZksPe3TI9)$ԩIN9Vơ\=2885N\ p)/a柛w9g_lױo8ݷ iixJV& ғRi{N^_oAŮE6Y7I$Nk$|Q)-*4Z)^¸%4Qm [I%.c-OV+C֧R#%ѨCe3i;w$G+_dy| Fzj$DI(=OA gj%v/]8qԯNIS*֩',Q%\44ZZ%D|Ǧʴ6&vֵI$%8(ԬƾS&#Z. }6z?b/|Jl{ץv&mpx4Z$”ڝ4-H%dGKfM:sKSRWeJAn]>s6应-W9'H]'uȫYvgK^\czp|My\鏩w/ËQ.)]\QiS`8uL뚛̸=J"ܻi\å'-)54Ue]:K\퓡vK xwBqrH\*֕TnzC.mT=t-H]SČ~Nu╏NÅ3f|͡G~B+Xm[Q7U{9"~jgK Zoʰ7"qJ,ekSeNGgϳ] ^.6:s}_,%eRg<5⿨z{ZPun#jRІ.6g T.!]xa c#jN$Zpl̋H WZu8WmMRýsĮ?Mco~sx TU҆Q :KDG4n42.<3/'^?6/ܠڒ^yrrÿr2\D}}B]^E~^T cɛ7϶Y[<֞[7d}2%QPqOLEQR\CIsj1?\}%tJ0e~ *sk"*)&ۓEi#{1J8Hrt|'ܝRr8)=ƔN'RVz:cf]F7bZyZUȘ4x8,#JG̒?.W9XnO]KO]%]ƻ O5Γ/3qÓj؍/r̺rƵ 5\&m6h.xoeX[=<3%< lZ"2h\Z[&jW3ejm?k&[]ųj+{N{66leu_+lj]q* 7g*knأYv= q ەdxЬZ|%GUrQ3jLŒqET]1% qkXYūYc[7Ś]QY\jko\</Lc7+'hMSUc6qXyؙ~6#ѯv.0$BQi5YyIhɍiy=KD!n3Vm[V%W-B%swa97ajۗ m+9~]fKq|Ddaˑ0A]_v޺mM5* F-BYHJ5}q>ʉ.6hyDmpD׬'-_v5;5[8K[viJ.3dR:oYHHh9I7:۽fi+wm^ [)odPѱ52CZUJicSw\&_s0uBȍh32džzQflcd^m|7GѹE!fO5]]H9݇ZomT@]?5B:Z߂'`V_+/MSKX߆ޠk3?o7y:4R/7þ] iG߬aBRU&?r&/} cQߥGj2?C5Yśe7hU=?+ x龳f-܈czW^7p%5|Y:SJE\U-(a_cƣUǽXXKiȞNlmۊڭڄR!**ܤMeȽ$|X5(Ź\rJ~ܮ]>'HB0cp XFr_c?f?7<ukSgov¥iG>>䙗i.+t+bOjIܶ . i^:nm}s}(3>NZ$2Qg([".>i.ƾ)B̋M8+"- >eE6DݥJnJˣt׻ 5.˅nJGwZD~!i۶a,Db3ZQ3O#KO5/֍ozuK'GbRi᝘NV_ҝcvם ZoX}F6z 7e5_e:ۓj=AB+iܔERadMBq*ԯ DwI/Gy*mĥiRKg6skY/#SN4e$-yXM YL?^ĸNNӪ{$r1JJRSLO]Aqm>V/s[~i/j+m>z}eI"Qvp]{ZԼ:{vPAG2=T͡@ڐ#u"E*>C;o$~C#_d/HBq^YRٽzIKbOm\~żjFFGdiQ(*/i*#.FF]©m=BmpQQQSP&Ҫ!T&^>:y)$ˑÐFčI Bӡ-t!bM WҦŶ'UZ=}zvn~oT/\ǒ'nr8 AJIӆz<^uߖ4eFC1i+v!3qNyߕni?4JZlmYFXFۼO0B\m[ tʄU3s"Sr(NJ;SKW72L4̏BVdf^Ҹj\]ȱ۪(ӷm?J-KEmWڽ^4<8qu%9pŹW~877ܾeVгS(յe^C]yX͹! םm4FGȋ\y'Z FX7e)|Gjt߹#gb\ŧq_([R8[qU$Z (ʻezV2V!iQ,i$JE˂٩ a(GK'O{vnBvryRd-RK4=qxZJMl_CuuIz @Rt㮽޳!|68\-l[џ84-2Pu" RJ_^OL>G1~XnBŬw6J0*Uvlږ1N G1q9IUm*'oWu][&UyYZbBZRZNfEJf"+2nF~Eû7n1xv.RUM$6 lAxSQJ&n5ܞwlEói"#>4׿Q.nEq7Oko[1wg8ZQwZYiqtm&~">Bo?w͡ni2峋NCEy Ҕ+%ZJ ʩq*fpˤl,~^Mχk1+:ݕ z&Y`KLӪУDr3[*Z :(SL&ݻ۬Vqsyԭs x|iI߽zZrg.:mp%6ԜvgmpIUt;QbS.Է) ǨKSV,*lڌ|5Jt3#NP.=+OZ~/G سIgbꥹJnl_DUM\iM!֔wVZuԺ,yV.Q>f v:݇WiaŸN5Ҕ[M7SsrvǣrMW= \8ZW-jsnڕ.ZnF2qt ً[ٻޘY۷Zm"Jxr&NAfA-݌to9s359݆mZ+N1-qS$D=17 x׵+%_ ve4ir6Z$FDڗnFtOr'7'{9C˨ꤡaYoace{Refnft RR"4%ʌm:Sj3)OdInTO>X'vxV#jܮw9Fog;5.~Y5\~18YQܹvj4+~t7S ﬕs %^۵ڴDZV69R^Y+rj$ԇoJKR5wB9C>Y:l+EǎS{ʲ{T6Wi* ^^9k/y/Cs\g*qڵgn4T8mERr|Ti+iPe;;.i\EBEJ 丬i9ɧM-ԼsGDrZ>r#R>~X9y4b棇9JwV۔%m(b[Tjvl}۩~nDԺ{Zo-YuK1vx.nWuO+jN [ٮ0%"΢CdTJK-RަH"$I(*ve &҉FzB,_Vpqp9m8werv')E;o&QE׵^d9˦j\_,ڵugZȻ̧8k+jK{wmr@3ӭ2 wFkzFVqs1؛.v'I%$[iT]D5Dl2 nk7qUxԫLS+sا3/ΖeZYK<["%-g/kRs:f3;*E ت wJ%)5&+&rw*霣i|sMҴ|;R+fm䡩.!**dӶ-6s6,]zAXMWjmnz%SJߴm2UXw7MQ%<!tKys#P,W>s;3IYwx<+i_\\\U6 u7P|xbn_k&ӓVOe䦒 VUr,-㘘"-LZeOSҠթrEvq8Kf%5%&K"#%vD/.ZYYŏ+p$nZkvއuW9㓱Z G wYIFyf)?ƎUm5ԉ/'k84{KO:rQI}XRuԪ|*lu)3qZ[mSm5R3".Xcَ5c®ࢫI*۳~wRϿQWޝ(EJrri&ۥ^ʶ齲Im|[yb;mnm֩uiܘq>E+Ikx߄3r33-5𹻖09ϖ9[Tz~mr5NsWl$oPusޛ^{Z;);sڹf\3oٹZmԉ/'k84{NO:rQIBø8Bݱ3n֤DiK4u& ofSȒܩx<˘|N0Fչ]qsp"}! QWw@t4ӭ+cO5%]'*{eM߲DRO1y*q8w++e!c߶ܪlZWّM欼 CQ̼빶lX{vib/V/ ai;x6~]+z]MWB>re-:lgk}պ!#9?%܋V-c[z!W?c7YNm/jRr[HOzԻefճ0q15Zp#rkQQ0tU-AmڵP/cȕ?0cZYj;:0ZM=D6g ?'UN+ձ[K ܖB2'xq9{|۫N0ku 7xaj;n\ 2[VznMlWiKbSk))f..)Km)&bGZ=>OR܍W:j'rM'wYz&/鶧{Sʵb"vջq[I-ՌZH._x*BagC'T(Q:$ͳQcMCKy?3g'ߝqnT);qs #ؤZ}OOI:cfnc8W~qy.;^pVl]Hԓ>^H^@7-AA܃nmL(uWܻS߿ Td95Bdh4t6*dDh!EhI[iŨ\L.&Nc ܮf^;$R)\rip9I|ٺ?#R.ZDZ;/]nݻqs\QE9M&Bd ]N mN*D>tgbK>+ˏ.!23]BȔR1ɝ^j'k2ƮqBQq[$di]icV/e`޵B.FIIJqbi>Ӥ|p; 6${)RU>_e}^dzdfzi %ekRVUS?6'hׂ)5.\+qUgzE2C˷ecŏ^֔ibk shesFWJ#~> Wk~ݨ}ڶ>ơǚ)׽ZƉo~B-ڼrvoE:Ʃ3ۣK7+Y`WirS):{>ڛ}:wԨ(J_";6R%[u&ƫdZ_\'np| RJwNeTW,=rrbnkڄ[M3ܴz)3- R.?:okۼ0TU'w{6&w7j1z3ON'fGoO?)S_bQ_¿R(^ԴԴG.EtMڇ&RUiW uQjU> Kiu1d<ѥIQ'RQ1:O/lŗᏩiʂv&Jc{D5 Tt)1.n[n۶X}RjqnOʽ(~[Ns{ސ⛌uO,kgo֢dRNQȄ .'6W!׌P朼tdZjFGE"]K@'i۪N;sI[{SOzk>`rRR+!σj8&TjlvA̷Q?HyjyLHNտJMjܶT۽lG?SnKN%<‘ nq[N0Sq[Ta(&t(|HGO~gvkݻTR4&Z$#ViOY1r$6YF?e4U/Mvxų:zbU^gQQ+NW_'4jfz^c'#`rvrڡ(IJ/J ݦ6 ]-CW |_{v*_q3^DZ}Ic6Uڌ8p7{crZq5ki`)mU6|-Z5^iEz3P=:Cu7DF'k%}<C-޹ֲ̱#\,(f88%X-N(ck0VLR~} G"-8ӏ/ϰKq?(#nrVTmZ;zióM4 m |UT'C^_1X.gXM{%ʤd 4\ovN":"y-,T)fLQgۢr=/CƹǨJVr[a+!rT|%Y\ٱzsS>jͱ.oOc6f$q% ǒGo;n[];ߎjrk{~\VۓNIGn:iqxo |~t5)Rxעri{Vi&NUOl_ѮMfsޕkЄay.0P{7N((BaIP$ K"U6Gl ݙqJRu+qN$ m#*p<|{:>-Ev=86N*MM긭U*uѾ?/^o7;'u,h4݌xښRM:5.(/ \իU.{F^rmF-Jɷ.>Q"[4xT^OZ~mK}T0ݛ^SAo9u?lX(' qj%=X}"^e4wˠ|rܫ 6I\Ķ;Ӻw!'ڍWg{ i U_9Avhۣƾ+:vs/MK[ɭīe{`Zgb}r[i'GE2J7Nez579wRq+Un ]J.cJ4M:h箽Wxxm^ pc\wcN%'My $$| :$Fqɏ¾^қP9J6Wxvu}ݵP>Z'FFdg"-; [¢cmWkÎT8nG%ݣ7*\խCLRYZͤiD&J#'ehbSyXK|y*ӞpS̍R`[pTr/Eg)K+92{_ n3zwz'oŸۤ+sOj J:`T>Cf*lwd\fYOP"R E֢̔L4ɥ :;.b(B02rJ蠟9>V'9M%)IqnhP<%,r'P/vNSwr#w"ݨaqc(|{kd=^0jTMR2ULNz|.<|^PfY22##!,K~E BEJۜ&jRNsHަޛg\r,v؜.jK3)[EJ2ii{KEiHP^&]Gn8x=K}Wx/KI9-ϵwQ%spܾ[^R}S3$qvq8M[ ozKxcqmJ/ӿ{_}7&ݨ\f6ZSyQz& 7ۉ[8~UNn|nkiTB+4RI8'Nc%tn{!]Ȋo.nEmʱn𵵥J A+wy#+ikǒڂ;՛s85'KmE:Ђu""Iģ5p=БbTY-ͽڔ詻ngL2Q}$de# fs^o{DUUsfwӶ;s1T,ǤtޒQ\෼J=.tKU,7čJ5 N$y3kdSMQU~mO[03 $zAڟsF5^뜞"Կ QHmrR"ӳηer+ҔZ]hE-6Jmt'ޒ=O[sQj)6K}?e4v_KfZheޓ=BV[bY}lݒTTЬ{ȫvO_qpRApVŗ 6ju=*BR)g "O1yhb=tqJ gtm\b3RY+JQ^Ō֍\յ\>+uSi{=x ^w;uӘ#ĸzLn*$anok߷CBӷ}5Yqvdž<( "_OWit5:EZj2 B ρ1̊fi[n!HQF82q1牙nqnEpT(2RMoM4ϳOu ':֧_Xjsg jP^(ڙ{2%E͖j^}ZU[Q$'U) <܂%!s"m R'G5M0<+zM6qYm$ڕ$3ǧH]?o2N<8F1̻r_my[Rf59NjpzBnl7*{.QP 3N&^BLJPjAHCK2Q}$#~YMq8 k(MFMU)8MEqTy+Tʞ-ar5yܕOXw!e;q-Jqܶ䓊Y:LC UE{/t>r"lI9)3KJjϤA 6SEE$d߇3KG*En|P\ԭTn6I-ƍKTj<1H_zwGr19wF N8ݝ+a9ɫM6mhePi%mmD! """"""*1bRKrD"vnrM۫mmĽm]ӡiG~e"˩ lhRTMk^MX["Jݱk7_ޕ*DqĒ&flՒ}`W}~SմZ{ĕ~wm*/{{ѹ_-0ط#P]xlڱ~Tn5wi*lڪ (JxioϏbqKYR|!|KN53 OS222$jzww%i}>N)E+rۥ7c$Ofl/LNث\6H9: FY󡈾I)fB֔JI_ ֣^: 9mY{66㒢7Uj]:.-os[R&gMF3˸#໹kmjq^8W"PΦURjʄWa˧T!͋ lW48JB2ko+ /Nw QwQzQ ے%$ޓ7^YL|r7!v%Trܥ &|M8~ybrn[RV gSn{{*#2#ԽᢏӴHak" ӌcwҜw&RJ07ױ>Ļ =^ BɆ)v32.M1=#6%̠tҤnzqMwԣ~s*%-j|_m*.Yx9Sz=)qE4 3pk+,`=kNRڥ=B=nŔNAx)Q$ԩȧ4z3t#Z2lҮYn$S%y- JzGpu|LBV7ZW#;Wwipܷ%(6jFG5#{$D"uۭ~]֫SrD܃fҎӾ+Tu>-ZTQ& N|$沸ii>eRWݳu'[O̻j8JۻEѩ[]vni= ڒ,[_%kC7I3Nv$4ɎЈeٸoUu:[}Do5|zNq=Tre%ɧ6&~DȍF]ƞG5q m]/w/ \ʲr8=oʔe9U(W"|S]uZd#?Se[W"ֿh][-7Nu:T=)R}.;ml*5Dlf $fF(̏T hiIUU4Szɕ t(%_|2 ~6eM;TƗK[f&]LK^CE2[ȏBOd;Mi|cx,^6;sیGpQ\NuJIFTJ~đArh* B"$H쉩eXPRj?sl"ԥ)su]xpԴY%VESH"ЋJǰ K&5^Ukzׄ8kEgS2h&Se\ Yl]WҶp-ZUvi7QS:4byqOo+[̺腋[6-_Fo.6[7$p&^ _GZԸߍkc.qqoI[9m߸YxOZЦ1uoiSH)P9Uʄjcq= S>֙NeR><;+ڌk%_qT].srNO?s[=vH[]RZHRMtᩗVؾ:/~u)ԍdg%=edVrISb{6vSu=(ܥ)mTv/J}̇8 S3ad:^hBSf؉OɔLhI_1d8,L><_A0y3rXq"'(۱;mFNII.v5_(^q~X>y{3צ I*Vܛv/jW' T'NR'j%ꔩ:mJ3SB}΋!-H-RJBТQoedi9tjENenPpke.%4]#{:>mkEɱdYWl\\\'nRM4&U>?Ќˉk÷!𴪛]]5}UqG~ݏI"O~s6(Ļ)qO~h}uԕd}Q~G,oE!&G&/]_H-O=o{k\̭bkv.Ô܈+;arZx)m?M\3lU$mk-CFXjTv6u' g:Vn_*qk:VC A%'4JV%EY)#BғO4<e׿jQQ]yUr4=wm[K1r׵%Iũ-O}|kC;/VcݩWZ)EHdžTru]8hgĵ-;=>U_ InvTm_jBM+QiF"9*{DI/iuo(=TzϖmPQl_v4z>T*ȴ>YF;ε\t]EH4ꌇ[VrLzef 2T^V>g2~kg5~Nק;{~Z~W}&ŒBӿS2$J?~(Yœ"˲ߩ\O]: J׉ښT{mmIѩn3˧)4LdFZ/zUG>U> n 5& ϴ-KJi2o]uKljvK3$bԔҚV旧iY5.ίfi96v7!v))FJM4{jG~Jt/lUE%pTAFe4qQk\ve۽/u/Im+W')v{\-E|Pms7߮DZRr۞/mu*1ՙaB܆ -xg3#6ۥtRogʌU)׎]ZҞNnŞr}F1Nnޞ;cZ{N}ۿMiuxʉ*3qi'9KHQ$WJxXyرŔe~[v5~/jN9Q4o6rJv FrdxM*iRjMzUinHdн7ᾞS=S'7 } ̽zt7K|_g J=Lq+/Bw_\ۧx\HJUPzQ<hqF[V0x==CsU7q|^ {)Iq38$_A(VgcKu06Ƅ"%i~_ˉk QCܣB8Ku/񋇵u([w}$F|8TՠI.E !;RJ^}MɒD_q2];Ɖ{5}*n7nEInO{Mwv}&q+v [V}Ĝ@%>#dXQ$f;iep.GquixVt x6bj͵mlKقQ[T]zs/&yەnM'W}!Fp_d^Tu N{ɻ'l{խ2.sTu{W^H&;1s)Pӛ6>$mě;Łnj= fLT)>׸+qReɴ[UR\L*P/!$Ӊ3Q 'K=m~6XqW3^W+ųO_[F$rR*u"T%@O +%# ]˽!aܽz{ͷvQh쩎]hGތ5ɇ*DzJDRNLi 4:{~2FmXY-zzĽ^f=]uū{/+&c:Ma{ĝDp2m܍kHș/(--m_vݮK(V{R}.k&yƴ7i^4@3f sK3^Ř˸B=]?gt5KbZB<e;kQLpxuWC}n 5ҴepB##~q= `x]KWF {GfŲ}?G.I9pjWkU]>={7q{kO/^I3==f1ɏ%nnʫ/Zu_yXN<57ۍ'vy/"8넭M2eԷ&Y,в33%IkjMr7xf nmQkX4踼>a-GcIeތw&U=-:qnW)z¥j :WqSZvԒ#j"KrIU)%qrmRoDGQ~SYRsu*V)  ,/x)MFD6O#]z 96[Ui(JRfw'y$GeUީkdMF-ݻ98F2d[o{Rn0n-xsV6Dh|Eb2E:KCOӪv4SJCr"J!!m,hRLD| ZYFm/X~ΧfrN&4Ƒ=Z9Mh.Mܵw/BdrܥniŪ8ɧ|y%œ[M=_tj?F!z5\evM:\ ~F-sg钬OWq“iiȍ<Gi%%n2rqͻllƑ)okw7}\Uk-:&fj솘XerV9yZuʼşdFC=rmo%~ZN78X(N)_7.Εn1MpJ}62jjJdI";R5&iLԸc:jmqiQj$ujp\{;v5B񥍪Xn Ą4qOERjzN(Ga٠䌡)p*v(J7#ZۻZ8O W uONb+^Qipv9GvֽƼϯrYƖKGJQDNPhRJjᡧC"21"9ѓS1;R_O7/WGz)8fE%F2ukmvSov/iZ&/]~KmI[:^~ͤ\kMi稜\ywJt3W7 8Ʒ~ݥeFgѼw"8VVSج\뻆}ݭ/J6Q)d|)zU3>k\L=;ow֯gN3pKѫ|wmkZ$z^2R:E)f>ς нd|#׆?\ǔpV{;\$ƵE%-ͪm0S6[n< kE[}mvE4DDZ^$OZ0*$~XUv҅B@^?]so#%ojw;Y#SxxueBگy v^i-)s)zV jC{7Gt.w3v,ygg8s]aE_,*E tY5k٨h=o"m泏:\6w噓aiL׎n^c\75AGkЯ0Lf46َ`egZ˓p/k;̛]kq!ݸzpԭG"}R9Ve>ˏHUjJ-&7nrnwG*Xv\˱/vN}O)ʼn&CV͍f̵]r\PMB-6Du-#RͰtRN^)mT _}nSȕC*_xBuTkJW[`ɩ`ejvsngP ڻ.-WUtܑqԹQj)t;vN&RNũT+8%IXӃ5fK՛-d9 ]CƑm|nZ-6=Hz,*aEm W3VzRšdY~Xf׀Xx"]s;)5u*ُHB BRGS6bݶؿ 9j[1*jױga7oX CUI%0v#~\-O-Ꙛuɷ쏪&5mY٦M`LJ2qK~HZbr =N'YobI. (^ ׾{_ ?OJ`S`3BN[}5w6:ǵ/iSlt=4F*d&T4y/#. ɵim5Uֲf 眕6Y7 fơ=3dϕq뚩$qTM-%r!$@A? ޾V0c~{[{;򥧅a~ڵ»&ڄv1ek=wb MLkNAԬw-x>~/r=e73VeVN)K%Sښe"+3uXuچrn ֺVzscJ峻m}vb㶓n\YbIUBT%*,0nov=;z꣓S/nSXSpl##k9mXGrZv^Gde!ŷRԠzQyjC]`gToPov{j~KRBMY}i[߶9KL2ԉO0K#m>wB[ٍ+n[[b٦DX ݲpo] [\m5qdT()mo4Oy9Ie b][wղmM~vmi۱~t \}$яimRk(L c Cvk7r9_r1 ;zv|F@KyZ[&jEji/"6$69ml#e]9s\{ScL}Ȣؿ0q/nZ*t,CLoD߉Njǚy=Pgmu6^]l-["çUʖMlʍp-"qmU>۷uFOJ%Ǔkx 'g=睋k[3u,{³WɘݪF]ՍeFX"Oy\,cچ=w/gn Ļ]#2? vqy-gXnR.^}ݺFs{ŝG]}e|#0mjx"ƬWكm?rgU^xVB":Dt>@LRbun~ݭ,w+v⪕;\U(RYa61>#Jm˞Μ9g9XKaG='u8gf}'qy#ɉw J]We.ʲ-<+&q%s?2dњztҼn`cΤmmqMdz O[-ߩӲ&;[tmܝVnr">{x<8U+p:Ig]zjGkt,uzf}dؠoJaکqEq -(:d<պ=eKy[˗^%ZXkX[C2߱\ITTLGzANM￵i]K>UsOGDDD.ZF6* ҃V Zhz{'xp^`wo8r0h ZmJ5"jb[l=yUu7-;7IT%:jFjߖm0tzU'K)څNۧYJ)4IQ}^KWm7kSP>q;ނ#)'n7&׊r?óM{IwR\j2Qn[v pe#/tAF\ϵ225q֒om6z})6҅*oqDsMf CNIN=T S2t,_ѧ}kveMF0J\Rnnݙܹy[rUc-j{yGtkQ%s]5qB.Nw.JN1LvR Ui5J ZESQԙr):MJ+g}χ!2;q([jAud][ljVK3$ײSJI=/|&tl'*n۽f.frܥ jQO8>&Z];.|7T/C}$ڋUmP2Reҭ8hFF\L 3~e v\۫]ݝNmrnB%*]Z«hKc=BTLG :V74$=Ǘy+EX'4tn(I:Ѝ;Df8c,k1%dJ6.j6ź{N~l6&*fœI7 WAlGOu-ҢH,,(ǔe뿋쩨kM܍ZſgRvQ' 9)?n|er˭|I|-fGK.rΛp8XV1%K6mvG+tc+qE&ǸC_Nm:l=_/m5^[dߌڇ.c<%:)tQ$Ow~-aY;UJ>=F)2[nk؆?훐M=l6[4(O.]2#-H^n#->&mp5~Fӛ+|| S,xag%qkEUzUgæBhߕP(7]kFnq?֖CpruZ6*rEڊtS|*tI*E}7R<,nUU֫^I7Q*mSly%rdȓd8hE<9oHhMfNSRj[i7D[Rj݊+kდq{"$$H?p\̅S?㭻;t~R߁)^/>Qj`yt[w ԛ;²~+ߔ_ YW~|o]?x^ᯛ `ʼn;g)T@vWn]>&4lp+$D̢1l|ȨF%-}.9[}w~ ԠLM9hСablfe&QoW!s?wjLK?s7yO>(=C~_nyǜu?v3vyo oI@qV-jeES^[9WoSܝh"l2C1a͔CiJ@3:Pճw=/7ovuk+\V;lDgն<[A+rX~d;m!_s8ݖ׷;;.0llUC+?i#_crʙ1~C.\–q ul8Hܶ2m`ܻM3Tov|Bs rɵ"oLS- DКw=Tv@f'6|YlD͓Y%׵-#Ѯo%:&!3o%\J<02;K87>^vgƓ# ;ݝmz^Y6=PS39U%~ &f# }o!muH;ʲŇ˷yvP+&.7e[3'vR4Yj̗IZ`e˽3o[WU{ m[sUbۋZǾۆl6~9'V*.\S2<Sd*zY[aŶ`]C$n.v^Ʌ dng>ەZ,Mmϑ :n6nϦezWqUJ4! ۇ4R! =>>Fn|Q[{pRO17ƕ~._I''00k=b՛o}Osðc2'o\3}ݭQ^2 . R1yKȣtAݿ-uܾw!`?1Whn|gzUo[ECWwjUIן)^h#1ɭ!/Z np;o;ΗŻkXs."6E`Z1 עӐ9Kl8qd q} 2Stt;#j>;խabONŗ=fwP1j)l6J̶|gV2`y/0E˛6+ԫ1? 6}KW c\KoKͨ2ۅFw–s*TԞLיuDx .kCzWXhy۶gLu|%TnupǺl-S* PRaLnT+c+*xl.v!.U=|; !_L̎뱚U=4hm:ٯ"y)$:>%(n}X'p[ȴ ^˒4kƓmzDx \ 'NqamP7nyN݅=j7%McSڵj%STy qXymvCg{w/w=wSW5r̹u erծˊsOm=DhEҚRb#n)QOxtվQwe]I}wCa'"[ۂ-z}2UuKP$㜉ԧ:mc<Ý>RoL?wu|%ҷ&K y_!y9 ??:tq3(UU-lkS'ɸ@jdzQˬR] EVPW1DJq2n:,c|ǻ̑;y{X,ۂ.u.b˕u.tKBjQ"[S園S`ٮdNبeJ&9Ơ ~0a(Vm٘L+Jr*vڑE( x0+tp˕ n';wm-ޜMOxX>{#2%jgb2M[`K*\5@8l'e=0u+w ֘鳾{y܀:R*Ya]"Ӧ%ktynlۣ65,3gU}{GYrb;ge'TKwǘ.,rpܚV]Tr,!dp /ԺU,xՉ>s׽~W5oTh yx?xrrx?)?ilbT׬,z$Ԏ.UH٠\U1pU:]JwSrGZq8àd驐,N67QYBӢD㏙W!Q25ϸo9ms-7-%3CihO.J鯽-;MZM8ku-7k9S$8]q2E(}bۏI[DKOK}3KUB^u %Y,u.-&f#]'܆o$x`Yu,dzwM;#oKxn;\[d7}Rb+*Y䛂ZuBӱl{j0O̓}LhK;[aֶaGL{Cb#S.T[>߃F]NK"u^LUʐ_ykW?!GRj29͖qa'0[npcDvV)qz9R)PۨM^aJx W] r>];eN3vxdmĘ(5W2K1䪖weF{mE/QP6\u54x5[hۮ-Nk”i[lUgL]J}5 S:EhiUrgHl!ŒJ$pe=q^b͵Q' ?6|R\,JA ڵ"TDꈭ:ymg`B5t%M] <N_zv2_Ortٵ/i/ReӮ*7[qүqEG* m"[I:6e^p"I$jԴęh!m)]GZkcjS!{e^z}+Cѥ9;R|/ֱeiUԏCNu2Zhcٗg$ݭwvr P8*7/Lk~I'Km1+MW%Bk|oOm>-#qj*|Dbѱkn|n{v#jĮqNpMIUm(7Liz;{ҜݞڝVƚVϬ+sO!OstGvxӉ']uӎ4g_ 1^-8ۦ k!)Ύ5O;YSB#2Zzχ;<.ֵOtge~.(RC#wFZeGZٸ6FFJ4e2ˇpJT$[wgV)q6muDGJ56q\I!̗ y/I~RtJ9kJ]Iy*'FN0s.[l!fw'y(7$œ WƫgyΙdMEU JQJv̋vmrۖ.jWR_M֨djYgSj0^\y'EoECjm$ IƩK>Z28J2TiJ2N#}.s cArl嫶nB.FIJ.)۔\ZiM>/hLĸ=C1s[?YMqp|94- 鮝𦔽/k^#NT(Y LS$6˩}{;5 )B۷W$qpN)qqoot}ZDVә;7TiK|6f3h$dԄ}fqݡ>Nb򗉉+ͶO]>ߡ_VtYf79ڰիF sq~prս|QM)g%l0ocJȨHz V;Bb/kLAcfPJ,ԭ{ƍgpjNR6VSI*$!yV足jᇑ.](EܣqM\qJ2eZT).<9UB/(B0j)mtKEj#׿fDI-=rZړj|'Nڤ]k*i$5qt"ݙPM6E4ke^Z8ۏhz$Q(R Ay2zfRñnpnkbkI:=j &ΝșW?׵d{+ύM'??XqeeĽ.[o=UxFS=ӷdZwenՄ]_X=ĭVa* pKs0ބۍfJ3 gz̚i|wnxtjc¼5${(1fXQ65ȼb̶Zkn>%FQMJXӡ{TZEVNᖣimT/37cNJUPnP҂ZOE~"-Rc4^b- FEͧtf5[)S!OZIښݲ͑;tvܡ+N)AR=hCNn;wL16-:特7M$=Tҕ-.R[HٷnXk sn[ҞD-0WS9p9:-Ϸ-jѬNu{ҹfv)[Ľvwfg(ٷfe+0mYj8Q1\ݧg]Eǎvڿc!4#j5̋C2"}BRriFp7=ô\TZ:\BLfj#I22װ<;صZl j 6:l"6]۸ K'6RTѯ^ئOԓV\?$x7s#r:Oh{ց=MmuHԷd{pN /܅:UE#Yy+(SgQ(Щ)RHzw>^Ѿݻ>mK&^ '$Jۻ&w%F|xfz%˳ L~3N?Cy9 v w/{ƿ kz3x> sXv}vP"@WyC z`'톽Dw%-tt yVY\wmuPYQA0iG-2JP,6/gˢ]u.-n!Zw.N7Q]Df}Q0({a\@=i_X7gFǘ8^⻲}G MZ1)WEfO12G+=-B@z\`||w6ċj߬m}UwRox֢I &c~XGP6Qndpvܻul'V7^FJt^{b^B(L~sѣ6@߿^xqU!ڙ5|Vpvef-uӥ^3  FSDɯKD%0r}FF穛r7 +o"V8tv̖NQU!5uFd"bCr^bJ=֤fM#ʳԷP0O-9xRBm\=`r-:;~3Tl(nXtXi%2Vٛ#vwqƴ`L@"H‹qW.j,JM5B[)WܺUeZFqc'V˷1W7V̾-MHФwn8N;HPSdݷC7&2j.W\τGŎ'Vb]c.x+Rx1%C2T{myg[qU|+m:M:շ8҉yWd)ՋWS%%:iqlʹmGwݹ WnNŤѩ5(9hTٵDdGUi-)vSs2 2{OnT$Xck n:¶(lASLeȔBjμPpTb2~N2~%^k[ܗ[Jzs0ӓHBKq[}JَA-$dFQgjxxFv4r/x*Rm% `4J(&iv7SkԲmSH1YWmx 8n.k']:Z˭_W >ڃXЩ. jTq%Aā[E}amc]D:rmHRiu:uӚӢ\p(5-q%e)(۬ҖȽIf<߽pr&ݫVfY91q2ĭEQgYbTGQ&,yL+N$[q*RVۉQ=FuTܻ>f>f㋳8N6$܌n)9&»iˤsX,݅܍ȩv+sRTpO}d?Wn/Inpȸ%O]StQO|v5\}7Zwb.AIVK^:wb{[uݯcytO߶S<{8KSRׁH̏N7ۚ[xkwYy_'ZӵF+>쌛ZUĦreE9F[24De{}@:ExWs-\ǻ7K-\JNvEk%:s˙#κ].oͳ;լ7wB6nwu:$L; DkI#Wz.:Xp(˅v$Sq,wn\qIN-e<5Oe+vuYTpcojUI_ާP8 O 7&VL8z$_B-H-[uh]T{|8=qVRN-:Ij:7PUtXϷmy鉿:RIM~33ӸS2#׳GdŲ5+/Bx{(WzȨ5Y㞎#|˖+ ط.|e<o/rߔX>7s}VE.OVti׽ .5nNJO"95{#q}Ay9do]R"M6z\tnNS-D!@3N_jicWsy*5uٮRcWv/.,j}=S)j5C^> Ie =gu9ӛqjtz]۪TMoߧI!Ǧ¶m:,"[L!{qAv-o 3{"KʼnrIkfٶj2ƙ؄S`7` k6jzޞ?e5G&6uʷ2%ԒRKE*G\Npom F/V |C0.q_eenƣ<5Oh'67ɪn[SĽ{ڔjǘzs;~׌(ۂ`ܢ1ƣ` _l9Va6%UQWh~P~\F^ZHR@:ۧCJ{ôGeBh;~ۧnU J\O+n2 RҠ)ng}Kh{5+S×ܛ.1ZjG)iRȤIN 4%{oΜ/eO[Nffd ĹK?nnԼMqX'܌nZvq<ķbFnͪaQ`5 s,M_լ?-@_{w{ӺձJ}GF[%v\5[ŒGkOw/ΜM9rjË%2+rd~+󲕛C9U۳r[aJǭm|˒LAʨSCq[XMۺoubfp:t+ΤĻo ][ zt-*67kvS7D·MMCQXm;)܎n_h%]4ܙnRk!]ڵsDUF"`R, &#R_*[z*ZqFXɻ]7|۵w+'pFDەs=r./ᐚm3Hשy yD"jHCr':sA65نѮ^o1V/ f;nFr3VM)e*- s D'H݅fӧ\*޷[k<7u<-]֍Q8R h|p=WlW3s%Q %3l}@U-K6f-NϿu|ڴmWN׮[׸F*mW\%r! C78:޳vBG7ŵ.JթԚ2x)ST!řn~9 W:Wpܢ件{xf8ٳwKE ҰWxVB\qBZ 2wMb[lGSnyԚ~z9ZmያvoN2Afnݽjf>)j3 !;gOYʹK" Wftڎ+׭b*2ϻK>ۢӱeyԪXISUm[z+ugX%0lϏnvg!;t{BqPj>PyvR7Cj]O%+ݲ :qiMj6W}3vC/R=4Som]ŗ=ю, TF6U_-\6MyskwMr&Q\wjKܩyMϣUj0*}RZܷSdY3>Zjqj6TgzpA/M`/Cmл,޻feE[/+uk^Vs1W$G(JsW2ٰu*߻q*Y޵.Wi:ur5T),=0uRmho.twܖiYwrWHntvEj8qhf`Ͻpf(R&>Ki%I7$QӖm-2 ~yߗQ-앑/ x[k8nw.c㩵k}]FkbJl:{.(˩n0Hqvαp7 귎.Gupx[N`Yq'+ruU7[ү+>!xrȫoSo]OC# d^Q]\>!ƛGw^Mx"-+%vdX-:M2UR%d>%l ioSu6lsj7D P>XxHz Ukà(n^Q V>5cVtWj SEiJdznyej[lE' 3kuٌNn4JW)gB {4 j6&]' m-(ZMEz8cz>WZ6#7+[,MR-Z!4ܓtCyE|umj1ƽvƷV\;%>Q :#Le(iVz5 4ũۤUWxX ^(ҔsլB2w-V ^R+; ˂M\z+Uwr+RWY⺧~ Q*JcYSNSλUd8in=v K낫k\IRרSUaCFmϿ5̗P|u ZTԕ}>oYѲ1sfP+sQkX8Gb~6r,s>^\,mGL+7[n-E\.Fqḕcl*Jmjb5 ,m]c}NXfeVlǸJ5eˡ$4%g~N p4Y*WwW٧<8v#;qԩTut,m"#Y D\5V`\\Lȋ];LȇiS6ϝZ l>LruR\v=ǘϔDg=ԈdFZ+M{=|,[;0>RiSi4,S5}yxw&(E7&fݙ4UՕ! ~'Id)]ǽu2K-fޭ \08Vڅ쓬=Vy^^ IhyKR-B#Ըr=]mܻӾ'*Umkoy rTqT_i,/8Q^<ݤ|4ԻO(܄"'5N~#m.(Ҿ2i6Uev&I*<}҄$eNtÛzyWJubW^iBW.܅Wڮg]irO6Ve90sgv.+sV޿aޔ[p?3q*FutUo*eL\KM'EG*ZcAFfG5J 5jj=MJ3OK:k˝'NMB7m3uFҕ\-Ywg%PRqMIyZGY9|μvn߻5cWݷa^+X֥vnݘ\v7m>Fgzv"-;Ew֝}1|RjN𿊀7g#֟*GQQ|#/bo]p$>_Un9гUbn9׃ErQBU-^vDmVh'<R[fdHT]*~}3j;nvjc7s-rӳ Y8[n[1pJx kX[Jk9Mn!_Nю6x:iZ˦U |߉^Ԛ݃hYxk &U^bwKk.[jE+P(˞=9j@snCv7%c_7=xǁ<l {t'酚+1F‹l׭:ݻILruǶkL-L(K0L1&>wXB(pm;1fpnlp֓%Skidkt(U +xulo'/ڕeN r=^pZZ:Pnj8Hf"48ijY[ N[yZٻ+=  ø:3 ?^ܷ^Sr#YK[UF?CuhC b]GM')mڏsNrܗI]ljq6VB. W,UK"YX5{c >Iqā> T:n!,5l2VzCl|+I[*SrjnS6٨y+x,@>П.g+!rn9>N|W>OZT_ut Y""v7|sfި;Pclm EùN,{'fNT%U&LfH8~1v>Il}统u6P˗c(WV~H^bMU.o*oOF0N:_:6Smr_.b+|ݶYY غF,mwjv>f*>QM뭱Sd:`N{l/⎱;n-z~"Gze퇎J5S KG9!Gn;N1 ݎ h6m|S?ɂ5'WOÞ 7|7^ao @mxGmi^jϽ>01Mf0լD3-2T. VXR"ɥV Kl J O7|u?bvа;6.eߓ|[1bmRr,eRz`z 6܎-ͨku͹Fː dPhYgZUj}nvX;z=gVեTv_J }\1n7w2J?ޘγc\E 1Aޑzq;\r]]\Y&[nsNei\uURje*Qk2CSl*xJz-xٶlm+|UjUؓ`Ladqiĩ!Gd\W~fz;Tn*PdRM&T4`չSWq5k훶(N"Ӎ% V]֦wb.nUO!u*J&Oӕ2e|Z=eV쫚΅g#+/RW:طnbi*Wyo)p{:ETKؚR(RY+r웓r(IF) VmȵNB:h Q1ғ|u8E]{,'$-TR[j49l*3"I鯴zhd>Q+\BkNF=.$ZR4Nwհ(IpNi.(Gi33#33e$FXK*NdWrud[r{xnk$v2ıh+J1TQ[#JQl[tRO]LHKٮ NӍnF񨔤֞Em'MILB"ԋ%dBŋ+p̿_17jzT~4pc Vo\ƹb9Rq-'1j;8ܗ)hE%DZKS<璸Bu*%*Yw5ڻ9ۣ^z4U; Ñk\U(o~G?VUĎ:?P?_F_Kߤ~ᓾI |pr.Ok\SklRhҪz{­P .}SktZ7UQ4ڌIM8̈eaӊJZ%FFZu,KZvln廐SNFIVtuNi?CM5]+Ph,{jN JSR$IS^tSUVrORYu.9WyP6 [Kiu m!X|]Y79ӄ)\ģ)pbڳr%*&ꑶ_-H*dzk)1 V3')UAϹٶWRxe'պn۫h7AR9 EAJeGLms!%D| A 5]/Q3eb̄vnVn%za\m kZnv([emqrIҕij|""><hjJשvvǕ|Pޟs}V~2&Z?+2N&Z4w@)4iSڪ_>/JN9Hiۏuf8'It[ȲR.hZ$ȋ_Y ~U<UUO*6b)Ovzڜj\R̋.$FsQuҊj^נ䈈y<zZIuP[}Qm=C?zN(Exqu/kn S-FzKZzOסӽjJ\)F3b!r5ٝ|;6 o=-3*λ]αb\abqRi-w޵⦪~b8Kpo)Z=>)ғ"5/GTZLE-輵f7ݘ۹~+&+w/7GFI:l33fg.N~۲\2|*cnermnnM+Fq"ѪIz%j =YW8@~gc/~?N'?)«qȸs➟n=k" X“m֮VreMh2[uݖ] *FܖN)MȐ`f0 g,C9̑o;ddudJ=In13:ݒvvdMUEJLp^,6t-@͐9'{7m{-3,>hnF;ѰM)->>+Ěz!R* :`e--m7nB\u{b U>[8֪]6^ߤLʦ\DFNo$$dͶlgno8OrsQ\l̯hRo8tuNo+ CTxu!2[>ctFpeޓƻֶR"3QrQuOѳgwQr;S~)6HhZw/GgVTmUf_yt7%$];zLWF̰xy2Ʉu!MCmš_0[W6jf#a-KLi+3Q7c^qg%s<1aYIQeZf+}>;S6L0]Yu_h9߻<ƅpmiM$AVvŚ,*#t2.8Y)-Zhshü97/#Oro"u^/uFgWɺ,p:6a,^x%$Yve^3PƗMnTP&yS}OJ '덫MH^:rXԴJۋ/rI;S*,+yz1hv)Qw^ڍJ2oL׊q(\fDj:^T%vOadɂnS}ZO)N*λdaȜkG_PIEO}нa(^iQX᯦-7^)%g'SJx(.S9zVɴZ{E ))ۅi/s7 VIV-|sj0*UBTHIqRf>FP$KqN0 R̻8j\GcC}IUz\i 6F)Q{Gҧ3qSzKj-Az VЛS-zy:8*mNk|D鿓ND2u+0Yŝ7kqm·?8Ib]u>˗^_>(]vӋzv+ݩ){vZrJ2RQ몋C$z [,pp,8mڊbR]Il .f~d/ݓs㓓mͶ{mgjQwn=Oic9ܚm4Q/6ݨ[TƧ?nԶoytf{@AzT{e{[O'ZRZt~AGD?s3􌿂ՉIw'|~U\ w~di:Kޱ)U/sU%njѩ&GSP^ǝd)..!^U` 1wX[aԇSxoFV6_扐)T 2Mfd=ۖͭiZ7KK Bi9%7@<3<ճԻU,},a}FRqɛr i@ONJvK KLN M, ʖv0n-]DwlI-X6ܶ$Jʴh5O+mOI+Ra瞠\ MG7BفjYo1#͖0V`Ѱ2M?c8>-Crt*JkIGS:e#hPKx[鱼>{5m;wcն&>j-M֥^َ) 6yȜl_w{-ō̱r> U=]iw3)r*]:K]6BdCTZ|>gf}LW}[$'Y5 &c -j.z6R 67MԷFMnÌwI7w5E}o޽+K ֵy4܌ȥW"COyR[q5Ӱ͙f[v"_#q{MV6܍3"u9BK(41ӯqˇc${ߝCi6I(OmθzҜ5k^:>Jzw.>qV8{vU[ڶEm|DžBz].KHjI]x;Mɗ{m,qZXr忇2u^RO2Z}ZێS[2Jen!*NDcrBUً4<ǼMҲs1Zw57c3&ĖڻzmP*FuJG1-dN:|OU}ҵgi2t~F^^Z.VxjvŧnNNh<:]^~NN+ge^g.SԔGFe߯'[vn'(ScJ]kܗ7eJOlRrfziݮq̋S"\*U<*W]k$FջV}? 7g#֟*GQQ|#/bo]p$>_Un9;l S VvQU%OLU{οmU6bZ1MTx%!֙Q7, J=!3 ;Q,ڌ;6ͱ݅q^&ߔ·n #WbwӖX.HtG)N&d̵zpI,n cu ޖUj+VXUp[w]N o.J6Z8Ts&utxln;~HPHS/xw`G\ʡ¿rj Z^vt"[L:SD\h0sUwR,}[x^X,R2Vn< ]2YDr[SRKs8tXb̷G?Ps Tv 3be,zVz D[/I.KOEQrm'$7|[J>r S`5յwT#\w1FTz\Ԛ &"ׅhSHrD\'r]~/>p;:Piuu:"9ő=tTaS7V2rӷk7mb[^WmPp*[y.Þ6f]cizJCgRR@UVl큝.WJP1N{/\whZ ػϧӱE7|E֫Sί.x-Y&pi%v''-x6r'Ws*6=DwwUu]=C?MK [yrtܒG$!WGqJ*%SAz ED[^)/tė/g=#Omd.|^n/sl׉g DZqemqowݮRzUܜ=ڽ-o/Iۖ;qVʘgPp|mm;6zGl9.8pwWgsJ2qPbe}}UpNjٯ}7TMQKrؽtEx%v w߾8%|j;~|}pK]ơ/ w߾8%|j;~|}pK]ơ/ w&~e_H 8PL7:%ʭ5Kw&U2vwR_+rm'}C7#rWoO&HoG?M$UR7{FU]u ;# !Wk`|W>׹潇9Vn)6)*ҹ{%qV4q>W1vi#T"Qk&GwxcJBJ- Ϸ^ˁxkU}ԣ/3.;]J=<*)cS)ROK9H=,r zX @)cS)Da^ԽQ gxJI=w֣gf*TRj

Corresponding author: Han, Su Jeong Department of Nursing, Konyang University, 158 Kwanjeodong-ro, Seo-gu, Daejon 302-832, Korea. Tel: +82-42-600-6344, Fax: +82-42-600-6314, E-mail: sjhan@konyang.ac.kr
• Received: February 10, 2014   • Accepted: April 24, 2014

Copyright © 2014 Korean Society of Adult Nursing

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 1,243 Views
  • 3 Download
  • 4 Crossref
  • 2 Scopus
prev next

Full Article

Download PDF Download PDF
  • Purpose
    The aim of this study was to investigate the factors contributing to health-related quality of life (HRQOL) among patients with chronic hepatitis B (CHB).
  • Methods
    A cross-sectional, descriptive design was used. The sample included 114 patients in a gastroenterology outpatient department at one hospital located in G city. Data were collected using a structured questionnaire from June to December 2009. The collected data were analyzed using SPSS/WIN 15.0.
  • Results
    Health-related quality of life was most strongly related to age, sex, income, occupation, and the care provider. Old age, female gender, lower income, not having an occupation and having a non-medical person were associated with lower HRQOL (R2=.03~.22, p=.041~<.001).
  • Conclusion
    CHB infection had a negative impact on HRQOL among the older, female gender, low socioeconomic status and not having medically knowledgeable care givers. Interventions beyond nursing care may be needed to improve the quality of health for patients with Chronic Hepatitis B.
  • Key Words: Health-related quality of life; Chronic Hepatitis B
Table 1.
General Characteristics, Health Behavior and Clinical Characteristics of Participants (N=114
Characteristics Categories n (%) or M±SD
Age (year) ＜40 34 (29.8)
≥40 80 (70.2)
46.19±12.85
Gender Male 94 (82.5)
Female 20 (17.5)
Spouse Yes 83 (72.8)
No 31 (27.2)
Education level Below high school 54 (47.4)
Above college 60 (52.6)
Religion Yes 62 (54.4)
No 52 (45.6)
Care provider Non-medical personnel 91 (79.8)
Medical personnel 23 (20.2)
Occupation Yes 79 (69.3)
No 35 (30.7)
Monthly income (10,000 won) ＜100 31 (27.2)
100~199 34 (29.8)
200~299 20 (17.6)
≥300 29 (25.4)
Alcohol drinking Yes 19 (16.7)
No 95 (83.3)
Smoking Yes 24 (21.1)
No 90 (78.9)
Concomitant disease Yes 54 (47.4)
No 60 (52.6)
Aggravation of disease Serious (≥5 times ALT) 4 (3.5)
Moderate (2~＜5 times ALT) 7 (6.1)
Stable (＜2 times ALT) 103 (90.4)
Drug resistance mutation Yes 57 (50.0)
No 57 (50.0)
Medication duration (year) ＜1 24 (21.0)
1~＜3 28 (24.6)
3~＜5 36 (31.6)
≥5 26 (22.8)
Serum liver function test (normal range)    
  AST (7~40 U/L)   47.93±100.29
  ALT (5~57 U/L)   49.67±74.73
  Albumin (3.5~5.5 g/dL)   4.51±0.52
  Bilirubin (0.2~1.0 mg/dL)   2.98±16.98
  ALP (38~126 U/L)   64.11±25.32
  GGT (Male: 3~39 U/L, Female: 1~27 U/L)   63.45±93.96

AST=aspartate transaminase; ALT=alanine transaminase; ALP=alkaline phosphatase; GGT=gamma glutamyl transpeptidase.

Table 2.
SF-36 and Liver Disease Targeted Scales of LDQOL 1.0 (N=114)
Variables M±SD Range
SF-36 Physical functioning 71.75±19.00 0~85.00
Role limitation-physical 78.62±27.32 0~100.00
Bodily pain 60.70±16.97 0~70.00
General health 50.18±20.32 0~95.00
Vitality 53.67±21.87 0~93.75
Social functioning 70.83±22.54 0~87.50
Role limitation-emotion 57.94±20.80 0~100.00
Mental health 65.22±17.60 0~85.00
Liver Disease Targeted Scales of LDQOL Symptoms of liver disease 87.54±14.58 29.41~100.00
Effects of liver disease 82.67±12.45 32.76~100.00
Concentration 93.11±12.38 34.29~100.00
Memory 91.35±13.70 30.00~100.00
Quality of social interaction 80.67±12.19 36.00~100.00
Health distress 53.71±12.24 13.33~66.67
Sexual functioning 80.90±16.44 20.00~100.00
Sexual problems (n=76) 87.61±16.19 41.67~100.00
Sleep 70.77±16.26 24.00~100.00
Loneliness 85.47±15.35 20.00~100.00
Hopelessness 71.97±18.90 30.00~100.00
Stigma of liver disease 83.27±18.71 20.00~100.00

LDQOL=liver disease quality of life.

Table 3.
SF-36 according to General Characteristics and Clinical Characteristics (N=114)
Characteristics Categories n (%) SF-36
PF RP BP GH VT SF RE MH
M±SD M±SD M±SD M±SD M±SD M±SD M±SD M±SD
Age (year) ＜40 34 (29.8) 78.68±11.76 85.29±25.60 63.24±12.73 52.65±21.40 54.41±21.79 71.69±23.30 83.33±25.62 55.44±22.97
≥40 80 (70.2) 68.81±20.72 75.78±27.69 59.63±18.45 53.36±22.03 53.36±22.03 70.47±22.35 75.83±28.73 59.00±19.86
t (p)   3.21 (.002) 1.71 (.089) 1.04 (.301) 0.84 (.400) 0.23 (.815) 0.26 (.792) 1.31 (.191) -0.83 (.406)
Gender Male 94 (82.5) 74.57±14.97 83.05±24.29 62.23±15.18 51.12±20.48 55.19±22.01 72.07±22.71 82.36±25.66 58.94±20.92
Female 20 (17.5) 58.50±28.75 57.81±31.60 53.50±22.77 45.75±19.42 46.56±20.22 65.00±21.31 57.92±30.04 53.25±20.08
t (p)   2.43 (.024) 3.99 (＜.001) 1.63 (.115) 1.07 (.285) 1.61 (.110) 1.27 (.204) 3.75 (＜.001) 1.11 (.269)
Spouse Yes 83 (72.8) 70.78±19.12 77.56±27.21 61.57±15.42 50.18±19.39 53.61±21.68 70.93±21.57 77.11±28.33 60.30±18.92
No 31 (27.2) 74.35±18.74 81.45±27.88 58.39±20.67 50.16±11.97 53.83±22.75 80.65±27.16 80.65±27.16 51.61±24.37
t (p)   -0.89 (.374) -0.67 (.501) 0.88 (.376) 0.00 (.996) -0.04 (.963) 0.07 (.938) -0.60 (.550) 2.01 (.047)
Education level ≤High school 54 (47.4) 69.07±22.53 74.54±28.73 57.96±19.46 48.15±19.94 49.54±21.78 69.21±24.25 73.61±29.26 53.61±21.90
≥College 60 (52.6) 74.17±14.93 82.29±25.68 63.17±14.08 52.00±20.65 57.40±21.45 72.29±20.98 82.08±26.30 61.83±19.11
t (p)   -1.43 (.163) -1.52 (.131) -1.62 (.109) -1.01 (.314) -1.93 (.055) -0.72 (.469) -1.61 (.108) -2.14 (.034)
Care provider Non-MP 91 (79.8) 70.49±20.49 78.09±28.90 60.22±17.13 49.78±20.98 51.85±22.33 68.68±23.15 78.57±28.41 57.58±21.30
MP 23 (20.2) 76.74±10.18 80.71±20.29 62.61±16.57 51.74±17.81 60.87±18.68 79.35±17.92 76.09±26.51 59.35±19.09
t (p)   -2.06 (.042) -0.40 (.684) -0.60 (.549) -0.41 (.681) -1.78 (.077) -2.05 (.042) 0.38 (.705) -0.36 (.718)
Occupation Yes 79 (69.3) 76.01±12.20 83.86±23.53 63.67±12.63 51.96±19.45 55.54±21.23 73.73±20.47 83.65±24.69 61.77±18.64
No 35 (30.7) 62.14±26.85 66.79±31.68 54.00±22.91 46.14±21.90 49.46±23.01 64.29±25.75 65.48±30.99 49.29±23.01
t (p)   2.92 (.006) 2.85 (.006) 2.34 (.024) 1.41 (.159) 1.37 (.172) 2.09 (.038) 3.06 (.003) 3.06 (.003)
Monthly income (10,000 won) ＜100a 31 (27.2) 65.32±23.38 68.15±30.63 54.19±22.92 42.10±22.57 43.95±25.84 60.08±26.30 67.47±31.43 43.87±22.65
100~199b 34 (29.8) 72.06±22.06 80.70±27.54 63.24±14.08 52.94±17.71 55.15±19.25 75.74±20.86 80.64±26.33 60.29±20.07
200~299c 20 (17.6) 76.75±9.22 78.44±22.44 64.50±10.50 51.25±19.73 54.06±19.90 72.50±18.41 77.92±26.39 62.00±13.02
≥300d 29 (25.4) 74.83±12.92 87.50±23.74 62.07±14.97 54.82±19.52 62.07±18.14 75.43±19.62 86.49±24.44 67.41±16.62
F (p)   1.94 (.126) 2.72 (.048) 2.24 (.088) 2.46 (.066) 3.78 (.013) 3.55 (.017) 2.56 (.058) 8.56 (＜.001)
Scheffé           a＜d a＜b   a＜b＜c＜d
Drinking Yes 19 (16.7) 77.63±9.33 84.54±24.68 64.21±10.17 52.11±17.90 56.25±22.05 73.06±23.30 85.96±19.26 61.58±20.35
No 95 (83.3) 70.58±20.22 77.43±27.79 60.00±17.98 49.79±20.83 53.16±21.92 70.39±22.48 76.49±29.20 57.21±20.92
t (p)   2.36 (.021) 1.03 (.303) 0.98 (.326) 0.45 (.652) 0.56 (.576) 0.46 (.655) 1.77 (.084) 0.83 (.406)
Concomitant disease Yes 54 (47.4) 64.81±21.67 69.21±31.12 56.30±21.57 45.74±21.42 50.58±23.95 68.52±26.23 70.22±30.53 54.44±23.04
No 60 (52.6) 78.00±13.63 87.08±20.16 64.67±9.99 54.17±18.55 56.46±19.59 72.92±18.58 85.14±23.47 61.08±18.18
t (p)   -3.83 (＜.001) -3.59 (.001) -2.61 (.011) -2.25 (.026) -1.44 (.153) -1.02 (.309) -2.90 (.005) -1.71 (.089)
Aggravation of disease Seriousa 4 (3.5) 72.33±18.64 79.55±26.77 60.97±16.77 54.55±21.27 54.55±21.27 71.11±22.14 79.69±25.95 58.78±19.87
Moderateb 7 (6.1) 62.50±26.29 40.62±27.71 45.00±25.16 32.81±20.00 32.81±20.00 46.87±32.87 18.75±23.93 28.75±16.52
Stablec 103 (90.4) 77.50±9.57 90.62±10.82 62.50±15.00 48.43±35.85 48.43±35.85 78.12±18.75 93.75±7.97 58.75±35.91
F (p)   1.70 (.499) 4.58 (.012) 1.72 (.183) 2.03 (.136) 2.03 (.136) 2.49 (.088) 11.72 (＜.001) 4.17 (.018)
Scheffé     c, a＞b         c, a＞b  

PF=physical function; RP=role physical; BP=bodily pain; GH=general health; VT=vitality; SF=social functioning; RE=role emotion; MH=mental health; MP=Medical personnel.

Table 4.
Liver Disease Targeted Scales of LDQOL according to General Characteristics and Clinical Characteristics (N=114)
Characteristics Categories n (%) Liver disease target scale of LDQOL
Total SxLD ELD Concentration Memory QSI HD SFun SProb Sleep Loneliness Hopeless SLD
M±SD M±SD M±SD M±SD M±SD M±SD M±SD M±SD M±SD M±SD M±SD M±SD M±SD
Age (year) ＜40 34 (29.8) 81.31±10.62 87.72±14.73 85.55±13.22 94.62±10.66 95.69±10.68 79.41±12.34 52.45±13.32 85.97±12.52 93.14±11.87 67.88±19.26 96.24±17.57 73.38±20.07 79.71±18.54
≥40 80 (70.2) 80.16±9.58 87.48±14.60 81.44±11.98 92.46±13.05 89.50±14.47 81.20±12.17 54.25±11.80 78.75±17.48 86.02±16.98 72.00±14.76 85.15±14.42 71.38±18.49 84.79±18.70
t (p)   0.56 (.574) 0.08 (.936) 1.62 (.108) 0.85 (.397) 2.53 (.013) -0.71 (.476) -0.71 (.475) 2.48 (.015) 1.96 (.057) -1.24 (.217) 0.34 (.732) 0.51 (.606) -1.33 (.186)
Gender Male 94 (82.5) 81.03±9.83 89.11±13.57 84.08±12.15 94.76±9.98 93.30±10.61 79.62±12.08 54.93±11.51 80.23±17.13 87.62±16.04 70.98±16.86 85.49±15.39 72.13±18.28 82.27±19.30
Female 20 (17.5) 78.02±2.22 80.20±17.12 76.03±11.97 85.43±18.68 82.17±21.39 85.60±11.78 48.00±14.16 88.00±15.19 87.50±19.54 69.80±13.39 85.40±15.59 71.25±22.12 88.00±15.19
t (p)   1.24 (.217) 2.54 (.012) 2.69 (.008) 2.16 (.042) 2.26 (.034) -2.05 (.049) 2.34 (.021) -.94 (.345) 0.01 (.986) 0.29 (.770) 0.02 (.981) 0.18 (.851) -1.45 (.155)
Spouse Yes 83 (72.8) 80.70±9.23 88.27±13.28 81.99±12.30 93.08±12.48 90.88±13.23 81.11±12.10 54.74±11.47 80.26±16.08 87.50±16.33 72.67±14.69 85.49±14.30 71.39±18.42 83.29±19.30
No 31 (27.2) 79.98±11.56 85.61±17.68 84.48±12.87 93.18±12.32 92.58±15.05 79.48±12.55 50.97±13.94 82.63±17.53 88.19±16.07 65.68±19.20 85.42±18.14 73.55±20.38 83.23±17.35
t (p)   0.34 (.729) 0.86 (.388) -0.95 (.344) -0.03 (.970) -0.58 (.559) 0.63 (.529) 1.47 (.144) -0.68 (.496) -0.13 (.893) 2.07 (.040) 0.02 (.982) -0.54 (.589) 0.01 (.986)
Education level ≤High school 54 (47.4) 79.69±10.16 85.60±14.57 81.26±11.40 91.48±14.65 87.72±16.25 80.52±14.39 53.02±12.49 79.97±17.62 87.50±17.42 72.44±17.02 85.93±13.56 69.17±19.13 85.37±18.55
≥College 60 (52.6) 81.24±9.63 89.30±14.49 83.94±13.29 94.57±9.81 94.61±9.97 80.80±9.93 54.33±12.08 81.74±15.40 87.71±15.21 69.27±15.53 85.07±16.90 74.50±18.50 81.39±18.82
t (p)   -0.83 (.406) -1.35 (.178) -1.14 (.253) -1.30 (.194) -2.69 (.008) -0.12 (.905) -0.56 (.571) -0.57 (.570) -0.05 (.956) 1.04 (.299) 0.29 (.767) -1.51 (.133) 1.13 (.259)
Care provider Non-MP 91 (79.8) 79.84±10.33 86.66±14.74 82.25±13.23 92.18±13.12 91.50±13.79 79.30±12.26 53.63±12.50 80.91±17.10 86.26±17.14 69.89±16.47 84.92±15.75 71.65±19.21 81.61±19.83
MP 23 (20.2) 83.12±7.40 91.05±13.64 84.33±8.76 96.77±8.10 90.72±13.63 86.09±10.51 54.06±11.41 80.87±13.87 91.67±12.42 74.26±15.20 87.65±13.75 73.26±18.00 89.86±11.57
t (p)   -1.43 (.155) -1.29 (.199) -.71 (.475) -2.10 (.040) 0.24 (.809) -2.43 (.016) -0.15 (.881) 0.01 (.992) -1.26 (.209) -1.15 (.251) -0.76 (.449) -0.36 (.716) -2.58 (.012)
Occupation Yes 79 (69.3) 81.81±9.54 89.70±12.09 85.27±10.09 94.47±10.57 92.83±11.32 80.30±12.12 55.49±10.92 82.28±14.72 88.06±16.05 70.94±15.31 85.97±14.85 74.18±18.46 83.88±19.05
No 35 (30.7) 77.55±10.09 82.69±18.32 76.80±15.17 90.04±15.47 88.00±17.70 81.49±12.50 49.71±14.17 77.80±19.67 85.94±17.14 70.40±18.44 84.34±16.59 67.00±19.22 81.90±18.14
t (p)   2.16 (.033) 2.07 (.044) 3.51 (.001) 1.54 (.130) 1.48 (.144) -0.47 (.635) 2.14 (.037) 1.34 (.181) 0.46 (.645) 0.16 (.872) 0.52 (.603) 1.89 (.061) 0.51 (.605)
Monthly income (10,000 won) ＜100a 31 (27.2) 75.25±11.47 81.69±17.18 75.47±15.28 88.48±16.04 87.74±17.14 77.55±15.75 46.88±15.51 76.87±20.45 84.62±17.95 65.55±20.20 80.39±20.82 65.00±20.94 78.39±18.62
100~199b 34 (29.8) 82.26±7.71 88.32±13.68 84.99±10.06 94.12±11.05 90.69±14.26 83.64±10.76 56.18±9.57 80.88±14.98 85.00±18.94 76.00±11.36 88.71±9.82 75.15±14.64 84.12±18.98
200~299c 20 (17.6) 82.10±7.29 92.40±7.51 84.48±10.05 96.14±7.60 95.00±7.98 78.80±9.0 54.83±7.68 82.93±12.84 89.74±1.67 69.80±14.36 86.40±13.76 71.00±18.89 86.33±16.75
≥300d 29 (25.4) 80.50±9.87 89.55±14.92 86.39±10.35 94.79±11.20 93.45±11.46 81.79±10.83 57.36±11.18 83.84±15.38 90.67±13.46 70.90±16.52 86.48±14.20 76.38±19.77 85.40±19.71
F (p)   4.43 (.006) 2.74 (.046) 5.41 (.002) 2.16 (.097) 1.46 (.229) 1.61 (.189) 5.08 (.002) 1.03 (.381) 0.72 (.538) 2.34 (.077) 1.73 (.164) 2.35 (.076) 1.03 (.382)
Scheffé   a＜b, a＜d   a＜b, a＜d       a＜b, a＜d            
Drinking Yes 19 (16.7) 83.83±6.62 89.53±11.52 87.93±8.81 98.20±3.95 96.32±8.31 81.47±11.79 58.60±10.02 84.44±13.07 92.78±12.14 73.05±18.18 88.42±9.32 71.05±19.41 86.49±16.00
No 95 (83.3) 79.84±10.30 87.15±15.14 81.62±12.83 81.62±12.83 90.35±14.40 80.51±12.33 52.74±12.45 80.20±17.01 86.34±16.88 70.32±15.91 84.88±16.27 72.16±18.90 82.63±19.22
t (p)   1.62 (.108) 0.64 (.519) 2.04 (.043) 3.74 (＜.001) 2.47 (.017) 0.32 (.748) 1.92 (.056) 1.02 (.307) 1.69 (.102) 0.66 (.505) 1.30 (.199) -0.23 (.817) 0.81 (.414)
Concomitant disease Yes 54 (47.4) 78.81±11.73 84.55±18.10 78.67±14.10 91.85±13.39 88.33±15.86 80.67±13.07 52.16±13.51 77.65±20.59 85.75±18.57 71.78±16.03 83.33±15.94 70.46±20.36 83.40±21.83
No 60 (52.6) 82.03±7.62 90.25±9.86 86.26±9.52 94.24±11.39 94.06±10.86 80.67±11.46 55.11±10.90 83.83±10.89 89.47±13.38 69.87±16.54 87.40±14.67 73.33±17.56 83.17±15.58
t (p)   -1.71 (.089) -2.05 (.043) -3.40 (.001) -1.02 (.306) -2.22 (.029) 0.00 (1.000) -1.28 (.200) -1.97 (.052) -1.00 (.319) 0.62 (.533) -1.41 (.159) -0.80 (.421) 0.06 (.949)
Aggravation of disease f Seriousa 4 (3.5) 81.09±8.60 88.15±13.70 83.04±12.36 93.34±12.00 92.00±13.14 80.97±11.82 54.27±10.94 81.13±16.05 87.81±15.57 71.14±15.35 86.71±13.37 73.00±17.18 84.36±17.55
Moderateb 7 (6.1) 61.99±16.08 67.40±29.31 69.39±14.10 79.28±22.05 75.00±22.52 65.00±13.61 33.33±14.40 67.14±82.06 75.00±22.04 57.00±23.40 62.00±20.00 37.50±9.57 58.33±22.02
Stablec 103 (90.4) 82.89±19.14 91.17±12.47 84.91±11.29 95.71±8.57 93.33±9.42 82.00±15.49 53.33±26.66 92.14±1.42 100.00±.00 72.00±32.65 77.00±38.00 78.75±29.54 85.83±28.33
F (p)   8.18 (＜.001) 4.17 (.018) 2.47 (.095) 2.61 (.078) 3.18 (.045) 3.45 (.035) 6.09 (.003) 2.38 (.097) 1.93 (.152) 1.45 (.238) 6.02 (.003) 8.25 (＜.001) 4.02 (.021)
Scheffé   c, a＞b c, a＞b         a, c＞b       a＞b c＞b c＞b

LDQOL=Liver Disease Quality of Life; SxLD=symptoms of liver disease; ELD=effects of liver disease; QSI=quality of social interaction; HD=health distress; SFun=sexual function; SProb=sexual problems; SLD=stigma of liver disease; MP=Medical personnel.

Table 5.
Variables affecting SF-36 domains and Liver Disease Targeted Scales of LDQOL domain (N=114)
Variables LDQOL
SF-36 Liver disease target scale of LDQOL
PF RP BP VT SF RE MH SxLD ELD Conc Mem QSI HD SexFun
β (p) β (p) β (p) β (p) β (p) β (p) β (p) β (p) β (p) β (p) β (p) β (p) β (p) β (p)
Age -.23                         -.20
(.008)                         (.036)
Male .23 .35       .33   .23   .28 .32 -.20    
  (.014) (＜.001)       (＜.001)   (.013)   (.003) (.001) (.030)    
Income (high)       .19     .23              
      (.041)     (.017)              
Occupation (yes) .21   .27   .20   .20   .30       .23  
(.025)   (.004)   (.031)   (.041)   (.001)       (.014)  
Care provider .18       .20             .23    
(.041)       (.033)             (.010)    
F-statistics 7.76 15.93 8.55 4.278 4.74 14.09 8.03 6.31 11.21 9.44 12.58 5.75 6.17 4.45
p ＜.001 ＜.001 .004 .041 .011 ＜.001 .001 .013 .001 .003 .001 .004 .014 .0.36
R2 .22 .12 .07 .03 .08 .11 .12 .05 .09 .08 .10 .09 .05 .04

LDQOL=Liver disease quality of life; PF=physical function; RP=role physical; BP=bodily pain; VT=vitality; SF=social functioning; RE=role emotion; MH=mental health; SxLD=symptoms of liver disease; ELD=effects of liver disease; Conc=concentration; Mem=memory; QSI=quality of social interaction; HD=health distress; SFun=sexual function.

  • Afendy A., Kallman J. B., Stepanova M., Younoszai Z., Aquino R. D., Bianchi G., et al. 2009;Predictors of health-related quality of life in patients with chronic liver disease. Alimentary Pharmacology & Therapeutics. 30:469–-476. http://dx.doi.org/10.1111/j.1365-2036.2009.04061.x.
  • Galant L. H., Forgiarini Junior L. A., Dias A. S., Marroni C. A.. 2012;Functional status, respiratory muscle strength, and quality of life in patients with cirrhosis. Brazilian Journal of Physical Therapy. 16(1):30–-34. http://dx.doi.org/10.1590/S1413-35552012000100006.
  • Gao R., Gao F., Li G., Hao J. Y.. 2012;Health-related quality of life in Chinese patients with chronic liver disease. Gastroenterology Research and Practice. 2012:516140http://dx.doi.org/10.1155/2012/516140.
  • Ghoshal U. C., Das A.. 2010;Evaluating quality of life of patients with chronic liver disease: Quest for a questionnaire. Indian Journal of Gastroenterology. 29:181–-183. http://dx.doi.org/10.1007/s12664-010-0052-x.
  • Gralnek I. M., Hays R. D., Kilbourne A., Rosen H. R., Keeffe E. B., Artinian L., et al. 2000;Development and evaluation of the liver disease quality of life instrument in person with advanced, chronic liver disease-the LDQOL 1.0. American Journal of Gastroenterology. 95(12):3552–-3565.
  • Kim H. S., Lee M. K.. 1998;Quality of life in chronic viral B hepatitis patients. Korean Journal of Psychosomatic Medicine. 6:35–-45.
  • Kim K. S., Yi M. S., Choi E. O., Paik S. W., Kwak S. M., Kwon S. H.. 2007;Quality of life and related factors in patients with chronic hepatitis B. Journal of Korean Academy of Fundamentals of Nursing. 14(3):331–-339.
  • Kim S. A., Park K. S., Jang M. K., Kam S.. 2006;Medical facilities utilization according to health status measured by SF-36 in male workers. Journal of Occupational and Environmental Medicine. 18(4):272–-283.
  • Kim S. H., Choi K. H., Hwang S. H., Lee J. H., Kwak S. Y., Park P. W., et al. 2007;Validation of the Korean version of liver disease quality of life (LDQOL 1.0) instrument. Journal of Korean Association for the Study of Liver. 13(1):44–-50.
  • Koh S. B., Chang S. J., Kang M. G., Cha B. S., Park J. K.. 1997;Reliability and validity on measurement instrument for health status assessment in occupational workers. Korean Journal of Preventive Medicine. 30(2):251–-266.
  • Kong H. K., Sohn H. S., Choi K. E., Kwon J. W., Shin H. T.. 2012;Prescribing patterns of antivirals for chronic hepatitis B. Korean Journal of Clinical Pharmacology. 22(1):81–-86.
  • Koran Chapter of Hepatitis B Foundation. 2013, August;General information Retrieved August 17, 2013, from the Hepatitis B Foundation Web site:.http://www.hepb.org/korean/.
  • Lam E. T. P., Lam C. L. K., Lai C. L., Yuen M. F., Fong D. Y. T., So T. M. K.. 2009;Health-related quality of life of Southern Chinese with chronic hepatitis B infection. Health and Quality of Life Outcomes. 7:52http://dx.doi.org/10.1186/1477-7525-7-52.
  • Lee E. H.. 2012;Problems with the use of questionnaires published on the Korean journal of adult nursing. Korean Journal of Adult Nursing. 24(5):439–-440. http://dx.doi.org/10.7475/kjan.2012.24.5.349.
  • Lee J. E., Kim S. S., Kim S. A., Han K. H., Kim S. H., Ji E. J., et al. 2011;Factors influencing health behavior of patients with chronic hepatitis B. Korean Journal of Adult Nursing. 23(1):20–-30.
  • Lee K. J., Kim J. J.. 2009;The assessment of workers' health status in the small scaled industry using SF-36. Journal of Soonchunhyang Medical Science. 14(3):171–-180.
  • Park C. K., Park S. Y., Kim E. S., Park J. H., Hyun D. U., Yun Y. M., et al. 2003;Assessment of quality of life and associated factors in patients with chronic viral liver disease. Journal of Korean Association for the study of liver. 9(3):212–-221.
  • Park H. J., Park S. J.. 2012;The relationship between income level and health-related quality of life in Korea. Health and Social Science. 31:107–-125.
  • Sobhonslidsuk A., Silpakit C., Kongsakon R., Satitpornkul P., Sripetch C., Khanthavit A.. 2006;Factors influencing health-related quality of life in chronic liver disease. World Journal of Gastroenterology. 12(48):7786–-7791.
  • Ware J. E., Sherbourne C. D.. 1992;The MOS 36-item short-form health survey(SF-36). I. conceptual framework and item selection. Medical Care. 30(6):473–-483.
  • Woo G., Tomlinson G., Yim C., Lilly L., Therapondos G., Wong D. K. H., et al. 2012;Health state utilities and quality of life in patients with hepatitis B. Canadian Journal of Gastro-enteroloy. 26(7):445–-451.
  • World Health Organization. 1995;The world health organization of life assessment (WHOQOL): Position paper from the world health organization. Social Science Medicine. 41(10):1403–-1409.
  • Younossi Z. M., Boparai N., McCormick M., Price L. L., Guyatt G.. 2001;Assessment of utilities and health-related quality of life in patients with chronic liver disease. The American Journal of Gastroenteology. 96(2):579–-583.
  • Younossi Z. M., Guyatt G., Kiwi M., Boparai N., King D.. 1999;Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 45(2):295–-300. http://dx.doi.org/10.1136/gut.45.2.295.

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • The Health-Related Quality of Life of Chronic Hepatitis B Virus Carriers Admitted to Yalgado OUEDRAOGO University Hospital, from January 31 to May 31, 2022, Burkina Faso
      Abdoul-Guaniyi Sawadogo, Abdoul Rasmané Zongo, Hamed Sidwaya Ouedraogo, Ben Moctar Abdou Djibo, Nadine Marie Stella Zombré, Lawagoulé Joseph Emile Ky, Arouna Sessouma, Ramondegue Winde Alphonsine Inès Sawadogo, Stella Line Emmanuella Pare, Roger Sombié
      Advances in Infectious Diseases.2024; 14(04): 737.     CrossRef
    • Factors influencing on health-related quality of life in South Korean with chronic liver disease
      Hyun Jin Kim, Hyeonsik Chu, Seonhye Lee
      Health and Quality of Life Outcomes.2018;[Epub]     CrossRef
    • Quality of Life of Chronic Hepatitis C Patients and Its Associated Factors
      Hoo Jeung Cho, Euna Park
      Osong Public Health and Research Perspectives.2017; 8(2): 124.     CrossRef
    • Related Factors of Quality of Life in Middle-male with Chronic Liver Disease
      Eun-Su Do, Sun-Mi Lee, Young-Sook Seo
      Journal of Digital Convergence.2015; 13(2): 267.     CrossRef

    Download Citation

    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

    Format:

    Include:

    Factors Influencing Health related Quality of Life among Patients with Chronic Hepatitis B
    Korean J Adult Nurs. 2014;26(3):287-299.   Published online June 30, 2014
    DOI: https://doi.org/10.7475/kjan.2014.26.3.287
    Download Citation
    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
    Format:
    • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
    • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
    Include:
    • Citation for the content below
    Factors Influencing Health related Quality of Life among Patients with Chronic Hepatitis B
    Korean J Adult Nurs. 2014;26(3):287-299.   Published online June 30, 2014
    DOI: https://doi.org/10.7475/kjan.2014.26.3.287
    Close

    Related articles

    Factors Influencing Health related Quality of Life among Patients with Chronic Hepatitis B
    Factors Influencing Health related Quality of Life among Patients with Chronic Hepatitis B

    General Characteristics, Health Behavior and Clinical Characteristics of Participants (N=114

    Characteristics Categories n (%) or M±SD
    Age (year) ＜40 34 (29.8)
    ≥40 80 (70.2)
    46.19±12.85
    Gender Male 94 (82.5)
    Female 20 (17.5)
    Spouse Yes 83 (72.8)
    No 31 (27.2)
    Education level Below high school 54 (47.4)
    Above college 60 (52.6)
    Religion Yes 62 (54.4)
    No 52 (45.6)
    Care provider Non-medical personnel 91 (79.8)
    Medical personnel 23 (20.2)
    Occupation Yes 79 (69.3)
    No 35 (30.7)
    Monthly income (10,000 won) ＜100 31 (27.2)
    100~199 34 (29.8)
    200~299 20 (17.6)
    ≥300 29 (25.4)
    Alcohol drinking Yes 19 (16.7)
    No 95 (83.3)
    Smoking Yes 24 (21.1)
    No 90 (78.9)
    Concomitant disease Yes 54 (47.4)
    No 60 (52.6)
    Aggravation of disease Serious (≥5 times ALT) 4 (3.5)
    Moderate (2~＜5 times ALT) 7 (6.1)
    Stable (＜2 times ALT) 103 (90.4)
    Drug resistance mutation Yes 57 (50.0)
    No 57 (50.0)
    Medication duration (year) ＜1 24 (21.0)
    1~＜3 28 (24.6)
    3~＜5 36 (31.6)
    ≥5 26 (22.8)
    Serum liver function test (normal range)    
      AST (7~40 U/L)   47.93±100.29
      ALT (5~57 U/L)   49.67±74.73
      Albumin (3.5~5.5 g/dL)   4.51±0.52
      Bilirubin (0.2~1.0 mg/dL)   2.98±16.98
      ALP (38~126 U/L)   64.11±25.32
      GGT (Male: 3~39 U/L, Female: 1~27 U/L)   63.45±93.96

    AST=aspartate transaminase; ALT=alanine transaminase; ALP=alkaline phosphatase; GGT=gamma glutamyl transpeptidase.

    SF-36 and Liver Disease Targeted Scales of LDQOL 1.0 (N=114)

    Variables M±SD Range
    SF-36 Physical functioning 71.75±19.00 0~85.00
    Role limitation-physical 78.62±27.32 0~100.00
    Bodily pain 60.70±16.97 0~70.00
    General health 50.18±20.32 0~95.00
    Vitality 53.67±21.87 0~93.75
    Social functioning 70.83±22.54 0~87.50
    Role limitation-emotion 57.94±20.80 0~100.00
    Mental health 65.22±17.60 0~85.00
    Liver Disease Targeted Scales of LDQOL Symptoms of liver disease 87.54±14.58 29.41~100.00
    Effects of liver disease 82.67±12.45 32.76~100.00
    Concentration 93.11±12.38 34.29~100.00
    Memory 91.35±13.70 30.00~100.00
    Quality of social interaction 80.67±12.19 36.00~100.00
    Health distress 53.71±12.24 13.33~66.67
    Sexual functioning 80.90±16.44 20.00~100.00
    Sexual problems (n=76) 87.61±16.19 41.67~100.00
    Sleep 70.77±16.26 24.00~100.00
    Loneliness 85.47±15.35 20.00~100.00
    Hopelessness 71.97±18.90 30.00~100.00
    Stigma of liver disease 83.27±18.71 20.00~100.00

    LDQOL=liver disease quality of life.

    SF-36 according to General Characteristics and Clinical Characteristics (N=114)

    Characteristics Categories n (%) SF-36
    PF RP BP GH VT SF RE MH
    M±SD M±SD M±SD M±SD M±SD M±SD M±SD M±SD
    Age (year) ＜40 34 (29.8) 78.68±11.76 85.29±25.60 63.24±12.73 52.65±21.40 54.41±21.79 71.69±23.30 83.33±25.62 55.44±22.97
    ≥40 80 (70.2) 68.81±20.72 75.78±27.69 59.63±18.45 53.36±22.03 53.36±22.03 70.47±22.35 75.83±28.73 59.00±19.86
    t (p)   3.21 (.002) 1.71 (.089) 1.04 (.301) 0.84 (.400) 0.23 (.815) 0.26 (.792) 1.31 (.191) -0.83 (.406)
    Gender Male 94 (82.5) 74.57±14.97 83.05±24.29 62.23±15.18 51.12±20.48 55.19±22.01 72.07±22.71 82.36±25.66 58.94±20.92
    Female 20 (17.5) 58.50±28.75 57.81±31.60 53.50±22.77 45.75±19.42 46.56±20.22 65.00±21.31 57.92±30.04 53.25±20.08
    t (p)   2.43 (.024) 3.99 (＜.001) 1.63 (.115) 1.07 (.285) 1.61 (.110) 1.27 (.204) 3.75 (＜.001) 1.11 (.269)
    Spouse Yes 83 (72.8) 70.78±19.12 77.56±27.21 61.57±15.42 50.18±19.39 53.61±21.68 70.93±21.57 77.11±28.33 60.30±18.92
    No 31 (27.2) 74.35±18.74 81.45±27.88 58.39±20.67 50.16±11.97 53.83±22.75 80.65±27.16 80.65±27.16 51.61±24.37
    t (p)   -0.89 (.374) -0.67 (.501) 0.88 (.376) 0.00 (.996) -0.04 (.963) 0.07 (.938) -0.60 (.550) 2.01 (.047)
    Education level ≤High school 54 (47.4) 69.07±22.53 74.54±28.73 57.96±19.46 48.15±19.94 49.54±21.78 69.21±24.25 73.61±29.26 53.61±21.90
    ≥College 60 (52.6) 74.17±14.93 82.29±25.68 63.17±14.08 52.00±20.65 57.40±21.45 72.29±20.98 82.08±26.30 61.83±19.11
    t (p)   -1.43 (.163) -1.52 (.131) -1.62 (.109) -1.01 (.314) -1.93 (.055) -0.72 (.469) -1.61 (.108) -2.14 (.034)
    Care provider Non-MP 91 (79.8) 70.49±20.49 78.09±28.90 60.22±17.13 49.78±20.98 51.85±22.33 68.68±23.15 78.57±28.41 57.58±21.30
    MP 23 (20.2) 76.74±10.18 80.71±20.29 62.61±16.57 51.74±17.81 60.87±18.68 79.35±17.92 76.09±26.51 59.35±19.09
    t (p)   -2.06 (.042) -0.40 (.684) -0.60 (.549) -0.41 (.681) -1.78 (.077) -2.05 (.042) 0.38 (.705) -0.36 (.718)
    Occupation Yes 79 (69.3) 76.01±12.20 83.86±23.53 63.67±12.63 51.96±19.45 55.54±21.23 73.73±20.47 83.65±24.69 61.77±18.64
    No 35 (30.7) 62.14±26.85 66.79±31.68 54.00±22.91 46.14±21.90 49.46±23.01 64.29±25.75 65.48±30.99 49.29±23.01
    t (p)   2.92 (.006) 2.85 (.006) 2.34 (.024) 1.41 (.159) 1.37 (.172) 2.09 (.038) 3.06 (.003) 3.06 (.003)
    Monthly income (10,000 won) ＜100a 31 (27.2) 65.32±23.38 68.15±30.63 54.19±22.92 42.10±22.57 43.95±25.84 60.08±26.30 67.47±31.43 43.87±22.65
    100~199b 34 (29.8) 72.06±22.06 80.70±27.54 63.24±14.08 52.94±17.71 55.15±19.25 75.74±20.86 80.64±26.33 60.29±20.07
    200~299c 20 (17.6) 76.75±9.22 78.44±22.44 64.50±10.50 51.25±19.73 54.06±19.90 72.50±18.41 77.92±26.39 62.00±13.02
    ≥300d 29 (25.4) 74.83±12.92 87.50±23.74 62.07±14.97 54.82±19.52 62.07±18.14 75.43±19.62 86.49±24.44 67.41±16.62
    F (p)   1.94 (.126) 2.72 (.048) 2.24 (.088) 2.46 (.066) 3.78 (.013) 3.55 (.017) 2.56 (.058) 8.56 (＜.001)
    Scheffé           a＜d a＜b   a＜b＜c＜d
    Drinking Yes 19 (16.7) 77.63±9.33 84.54±24.68 64.21±10.17 52.11±17.90 56.25±22.05 73.06±23.30 85.96±19.26 61.58±20.35
    No 95 (83.3) 70.58±20.22 77.43±27.79 60.00±17.98 49.79±20.83 53.16±21.92 70.39±22.48 76.49±29.20 57.21±20.92
    t (p)   2.36 (.021) 1.03 (.303) 0.98 (.326) 0.45 (.652) 0.56 (.576) 0.46 (.655) 1.77 (.084) 0.83 (.406)
    Concomitant disease Yes 54 (47.4) 64.81±21.67 69.21±31.12 56.30±21.57 45.74±21.42 50.58±23.95 68.52±26.23 70.22±30.53 54.44±23.04
    No 60 (52.6) 78.00±13.63 87.08±20.16 64.67±9.99 54.17±18.55 56.46±19.59 72.92±18.58 85.14±23.47 61.08±18.18
    t (p)   -3.83 (＜.001) -3.59 (.001) -2.61 (.011) -2.25 (.026) -1.44 (.153) -1.02 (.309) -2.90 (.005) -1.71 (.089)
    Aggravation of disease Seriousa 4 (3.5) 72.33±18.64 79.55±26.77 60.97±16.77 54.55±21.27 54.55±21.27 71.11±22.14 79.69±25.95 58.78±19.87
    Moderateb 7 (6.1) 62.50±26.29 40.62±27.71 45.00±25.16 32.81±20.00 32.81±20.00 46.87±32.87 18.75±23.93 28.75±16.52
    Stablec 103 (90.4) 77.50±9.57 90.62±10.82 62.50±15.00 48.43±35.85 48.43±35.85 78.12±18.75 93.75±7.97 58.75±35.91
    F (p)   1.70 (.499) 4.58 (.012) 1.72 (.183) 2.03 (.136) 2.03 (.136) 2.49 (.088) 11.72 (＜.001) 4.17 (.018)
    Scheffé     c, a＞b         c, a＞b  

    PF=physical function; RP=role physical; BP=bodily pain; GH=general health; VT=vitality; SF=social functioning; RE=role emotion; MH=mental health; MP=Medical personnel.

    Liver Disease Targeted Scales of LDQOL according to General Characteristics and Clinical Characteristics (N=114)

    Characteristics Categories n (%) Liver disease target scale of LDQOL
    Total SxLD ELD Concentration Memory QSI HD SFun SProb Sleep Loneliness Hopeless SLD
    M±SD M±SD M±SD M±SD M±SD M±SD M±SD M±SD M±SD M±SD M±SD M±SD M±SD
    Age (year) ＜40 34 (29.8) 81.31±10.62 87.72±14.73 85.55±13.22 94.62±10.66 95.69±10.68 79.41±12.34 52.45±13.32 85.97±12.52 93.14±11.87 67.88±19.26 96.24±17.57 73.38±20.07 79.71±18.54
    ≥40 80 (70.2) 80.16±9.58 87.48±14.60 81.44±11.98 92.46±13.05 89.50±14.47 81.20±12.17 54.25±11.80 78.75±17.48 86.02±16.98 72.00±14.76 85.15±14.42 71.38±18.49 84.79±18.70
    t (p)   0.56 (.574) 0.08 (.936) 1.62 (.108) 0.85 (.397) 2.53 (.013) -0.71 (.476) -0.71 (.475) 2.48 (.015) 1.96 (.057) -1.24 (.217) 0.34 (.732) 0.51 (.606) -1.33 (.186)
    Gender Male 94 (82.5) 81.03±9.83 89.11±13.57 84.08±12.15 94.76±9.98 93.30±10.61 79.62±12.08 54.93±11.51 80.23±17.13 87.62±16.04 70.98±16.86 85.49±15.39 72.13±18.28 82.27±19.30
    Female 20 (17.5) 78.02±2.22 80.20±17.12 76.03±11.97 85.43±18.68 82.17±21.39 85.60±11.78 48.00±14.16 88.00±15.19 87.50±19.54 69.80±13.39 85.40±15.59 71.25±22.12 88.00±15.19
    t (p)   1.24 (.217) 2.54 (.012) 2.69 (.008) 2.16 (.042) 2.26 (.034) -2.05 (.049) 2.34 (.021) -.94 (.345) 0.01 (.986) 0.29 (.770) 0.02 (.981) 0.18 (.851) -1.45 (.155)
    Spouse Yes 83 (72.8) 80.70±9.23 88.27±13.28 81.99±12.30 93.08±12.48 90.88±13.23 81.11±12.10 54.74±11.47 80.26±16.08 87.50±16.33 72.67±14.69 85.49±14.30 71.39±18.42 83.29±19.30
    No 31 (27.2) 79.98±11.56 85.61±17.68 84.48±12.87 93.18±12.32 92.58±15.05 79.48±12.55 50.97±13.94 82.63±17.53 88.19±16.07 65.68±19.20 85.42±18.14 73.55±20.38 83.23±17.35
    t (p)   0.34 (.729) 0.86 (.388) -0.95 (.344) -0.03 (.970) -0.58 (.559) 0.63 (.529) 1.47 (.144) -0.68 (.496) -0.13 (.893) 2.07 (.040) 0.02 (.982) -0.54 (.589) 0.01 (.986)
    Education level ≤High school 54 (47.4) 79.69±10.16 85.60±14.57 81.26±11.40 91.48±14.65 87.72±16.25 80.52±14.39 53.02±12.49 79.97±17.62 87.50±17.42 72.44±17.02 85.93±13.56 69.17±19.13 85.37±18.55
    ≥College 60 (52.6) 81.24±9.63 89.30±14.49 83.94±13.29 94.57±9.81 94.61±9.97 80.80±9.93 54.33±12.08 81.74±15.40 87.71±15.21 69.27±15.53 85.07±16.90 74.50±18.50 81.39±18.82
    t (p)   -0.83 (.406) -1.35 (.178) -1.14 (.253) -1.30 (.194) -2.69 (.008) -0.12 (.905) -0.56 (.571) -0.57 (.570) -0.05 (.956) 1.04 (.299) 0.29 (.767) -1.51 (.133) 1.13 (.259)
    Care provider Non-MP 91 (79.8) 79.84±10.33 86.66±14.74 82.25±13.23 92.18±13.12 91.50±13.79 79.30±12.26 53.63±12.50 80.91±17.10 86.26±17.14 69.89±16.47 84.92±15.75 71.65±19.21 81.61±19.83
    MP 23 (20.2) 83.12±7.40 91.05±13.64 84.33±8.76 96.77±8.10 90.72±13.63 86.09±10.51 54.06±11.41 80.87±13.87 91.67±12.42 74.26±15.20 87.65±13.75 73.26±18.00 89.86±11.57
    t (p)   -1.43 (.155) -1.29 (.199) -.71 (.475) -2.10 (.040) 0.24 (.809) -2.43 (.016) -0.15 (.881) 0.01 (.992) -1.26 (.209) -1.15 (.251) -0.76 (.449) -0.36 (.716) -2.58 (.012)
    Occupation Yes 79 (69.3) 81.81±9.54 89.70±12.09 85.27±10.09 94.47±10.57 92.83±11.32 80.30±12.12 55.49±10.92 82.28±14.72 88.06±16.05 70.94±15.31 85.97±14.85 74.18±18.46 83.88±19.05
    No 35 (30.7) 77.55±10.09 82.69±18.32 76.80±15.17 90.04±15.47 88.00±17.70 81.49±12.50 49.71±14.17 77.80±19.67 85.94±17.14 70.40±18.44 84.34±16.59 67.00±19.22 81.90±18.14
    t (p)   2.16 (.033) 2.07 (.044) 3.51 (.001) 1.54 (.130) 1.48 (.144) -0.47 (.635) 2.14 (.037) 1.34 (.181) 0.46 (.645) 0.16 (.872) 0.52 (.603) 1.89 (.061) 0.51 (.605)
    Monthly income (10,000 won) ＜100a 31 (27.2) 75.25±11.47 81.69±17.18 75.47±15.28 88.48±16.04 87.74±17.14 77.55±15.75 46.88±15.51 76.87±20.45 84.62±17.95 65.55±20.20 80.39±20.82 65.00±20.94 78.39±18.62
    100~199b 34 (29.8) 82.26±7.71 88.32±13.68 84.99±10.06 94.12±11.05 90.69±14.26 83.64±10.76 56.18±9.57 80.88±14.98 85.00±18.94 76.00±11.36 88.71±9.82 75.15±14.64 84.12±18.98
    200~299c 20 (17.6) 82.10±7.29 92.40±7.51 84.48±10.05 96.14±7.60 95.00±7.98 78.80±9.0 54.83±7.68 82.93±12.84 89.74±1.67 69.80±14.36 86.40±13.76 71.00±18.89 86.33±16.75
    ≥300d 29 (25.4) 80.50±9.87 89.55±14.92 86.39±10.35 94.79±11.20 93.45±11.46 81.79±10.83 57.36±11.18 83.84±15.38 90.67±13.46 70.90±16.52 86.48±14.20 76.38±19.77 85.40±19.71
    F (p)   4.43 (.006) 2.74 (.046) 5.41 (.002) 2.16 (.097) 1.46 (.229) 1.61 (.189) 5.08 (.002) 1.03 (.381) 0.72 (.538) 2.34 (.077) 1.73 (.164) 2.35 (.076) 1.03 (.382)
    Scheffé   a＜b, a＜d   a＜b, a＜d       a＜b, a＜d            
    Drinking Yes 19 (16.7) 83.83±6.62 89.53±11.52 87.93±8.81 98.20±3.95 96.32±8.31 81.47±11.79 58.60±10.02 84.44±13.07 92.78±12.14 73.05±18.18 88.42±9.32 71.05±19.41 86.49±16.00
    No 95 (83.3) 79.84±10.30 87.15±15.14 81.62±12.83 81.62±12.83 90.35±14.40 80.51±12.33 52.74±12.45 80.20±17.01 86.34±16.88 70.32±15.91 84.88±16.27 72.16±18.90 82.63±19.22
    t (p)   1.62 (.108) 0.64 (.519) 2.04 (.043) 3.74 (＜.001) 2.47 (.017) 0.32 (.748) 1.92 (.056) 1.02 (.307) 1.69 (.102) 0.66 (.505) 1.30 (.199) -0.23 (.817) 0.81 (.414)
    Concomitant disease Yes 54 (47.4) 78.81±11.73 84.55±18.10 78.67±14.10 91.85±13.39 88.33±15.86 80.67±13.07 52.16±13.51 77.65±20.59 85.75±18.57 71.78±16.03 83.33±15.94 70.46±20.36 83.40±21.83
    No 60 (52.6) 82.03±7.62 90.25±9.86 86.26±9.52 94.24±11.39 94.06±10.86 80.67±11.46 55.11±10.90 83.83±10.89 89.47±13.38 69.87±16.54 87.40±14.67 73.33±17.56 83.17±15.58
    t (p)   -1.71 (.089) -2.05 (.043) -3.40 (.001) -1.02 (.306) -2.22 (.029) 0.00 (1.000) -1.28 (.200) -1.97 (.052) -1.00 (.319) 0.62 (.533) -1.41 (.159) -0.80 (.421) 0.06 (.949)
    Aggravation of disease f Seriousa 4 (3.5) 81.09±8.60 88.15±13.70 83.04±12.36 93.34±12.00 92.00±13.14 80.97±11.82 54.27±10.94 81.13±16.05 87.81±15.57 71.14±15.35 86.71±13.37 73.00±17.18 84.36±17.55
    Moderateb 7 (6.1) 61.99±16.08 67.40±29.31 69.39±14.10 79.28±22.05 75.00±22.52 65.00±13.61 33.33±14.40 67.14±82.06 75.00±22.04 57.00±23.40 62.00±20.00 37.50±9.57 58.33±22.02
    Stablec 103 (90.4) 82.89±19.14 91.17±12.47 84.91±11.29 95.71±8.57 93.33±9.42 82.00±15.49 53.33±26.66 92.14±1.42 100.00±.00 72.00±32.65 77.00±38.00 78.75±29.54 85.83±28.33
    F (p)   8.18 (＜.001) 4.17 (.018) 2.47 (.095) 2.61 (.078) 3.18 (.045) 3.45 (.035) 6.09 (.003) 2.38 (.097) 1.93 (.152) 1.45 (.238) 6.02 (.003) 8.25 (＜.001) 4.02 (.021)
    Scheffé   c, a＞b c, a＞b         a, c＞b       a＞b c＞b c＞b

    LDQOL=Liver Disease Quality of Life; SxLD=symptoms of liver disease; ELD=effects of liver disease; QSI=quality of social interaction; HD=health distress; SFun=sexual function; SProb=sexual problems; SLD=stigma of liver disease; MP=Medical personnel.

    Variables affecting SF-36 domains and Liver Disease Targeted Scales of LDQOL domain (N=114)

    Variables LDQOL
    SF-36 Liver disease target scale of LDQOL
    PF RP BP VT SF RE MH SxLD ELD Conc Mem QSI HD SexFun
    β (p) β (p) β (p) β (p) β (p) β (p) β (p) β (p) β (p) β (p) β (p) β (p) β (p) β (p)
    Age -.23                         -.20
    (.008)                         (.036)
    Male .23 .35       .33   .23   .28 .32 -.20    
      (.014) (＜.001)       (＜.001)   (.013)   (.003) (.001) (.030)    
    Income (high)       .19     .23              
          (.041)     (.017)              
    Occupation (yes) .21   .27   .20   .20   .30       .23  
    (.025)   (.004)   (.031)   (.041)   (.001)       (.014)  
    Care provider .18       .20             .23    
    (.041)       (.033)             (.010)    
    F-statistics 7.76 15.93 8.55 4.278 4.74 14.09 8.03 6.31 11.21 9.44 12.58 5.75 6.17 4.45
    p ＜.001 ＜.001 .004 .041 .011 ＜.001 .001 .013 .001 .003 .001 .004 .014 .0.36
    R2 .22 .12 .07 .03 .08 .11 .12 .05 .09 .08 .10 .09 .05 .04

    LDQOL=Liver disease quality of life; PF=physical function; RP=role physical; BP=bodily pain; VT=vitality; SF=social functioning; RE=role emotion; MH=mental health; SxLD=symptoms of liver disease; ELD=effects of liver disease; Conc=concentration; Mem=memory; QSI=quality of social interaction; HD=health distress; SFun=sexual function.
    Table 1. General Characteristics, Health Behavior and Clinical Characteristics of Participants (N=114

    AST=aspartate transaminase; ALT=alanine transaminase; ALP=alkaline phosphatase; GGT=gamma glutamyl transpeptidase.

    Table 2. SF-36 and Liver Disease Targeted Scales of LDQOL 1.0 (N=114)

    LDQOL=liver disease quality of life.

    Table 3. SF-36 according to General Characteristics and Clinical Characteristics (N=114)

    PF=physical function; RP=role physical; BP=bodily pain; GH=general health; VT=vitality; SF=social functioning; RE=role emotion; MH=mental health; MP=Medical personnel.

    Table 4. Liver Disease Targeted Scales of LDQOL according to General Characteristics and Clinical Characteristics (N=114)

    LDQOL=Liver Disease Quality of Life; SxLD=symptoms of liver disease; ELD=effects of liver disease; QSI=quality of social interaction; HD=health distress; SFun=sexual function; SProb=sexual problems; SLD=stigma of liver disease; MP=Medical personnel.

    Table 5. Variables affecting SF-36 domains and Liver Disease Targeted Scales of LDQOL domain (N=114)

    LDQOL=Liver disease quality of life; PF=physical function; RP=role physical; BP=bodily pain; VT=vitality; SF=social functioning; RE=role emotion; MH=mental health; SxLD=symptoms of liver disease; ELD=effects of liver disease; Conc=concentration; Mem=memory; QSI=quality of social interaction; HD=health distress; SFun=sexual function.

    Table 1.

    Table 2.

    Table 3.

    Table 4.

    Table 5.

    Korean J Adult Nurs : Korean Journal of Adult Nursing

    ABOUT

    BROWSE ARTICLES 

    EDITORIAL POLICY

    FOR CONTRIBUTORS  

    © Korean Society of Adult Nursing.
    TOP